{
    "id": "m4faimivvspigac4cr7popcoysgxvobc",
    "title": "Virtual Screening and Library Design",
    "info": {
        "author": [
            "Andreas Bender, University of Cambridge"
        ],
        "published": "June 28, 2019",
        "recorded": "May 2019",
        "category": [
            "Top->Data Science",
            "Top->Computer Science->Big Data",
            "Top->Computer Science"
        ]
    },
    "url": "http://videolectures.net/icgeb_bender_virtual_screening/",
    "segmentation": [
        [
            "So what I consider in this talk is the chemical space that we actually put into, for example, a high content screen or high throughput screen.",
            "So the question is not what do I do with the read out?",
            "The question is how to actually connect the chemistry.",
            "I put it into the readout OK because there's obviously connection.",
            "You cannot really understand what happens if you do not consider what is actually the driving factor behind it.",
            "Change the phenotypic change for it."
        ],
        [
            "And so there will be 3 three sections of this talk.",
            "So the first one is in current drug discovery.",
            "What I actually, the chemical space that is considered by current drugs on the market, and that can mean chemistry.",
            "It can also mean bioactivity space, because in drug discovery, as you might have realized already.",
            "But you will certainly see it after this talk.",
            "There's quite a lot of metoo activity.",
            "So historically, when one company developed a drug against the target six months later, there was another company coming up.",
            "Trying to bust the patent, so just change the ring slightly and to have a meet two compound with no not many additional positive properties, but simply another component on the market.",
            "So in drug discovery is quite driven by that, so everyone jumps on the same target there and that creates a problem.",
            "Also from the Machine learning site.",
            "For example, if you want to evaluate your methods and you do random validation for example, that doesn't always work because we have quite a lot of me two data points in most datasets, so I will.",
            "I will cover that.",
            "In the beginning and then there will be 2 topics and that's the actual topic of the title of the talk.",
            "One is virtual screening, so if I have one combined with an activity, how can I pick another one in chemical space?",
            "Usually that has similar activities and the other point is if I have no clue what to start with, how can I actually assemble a screening library?",
            "So what are factors I need to consider that I can put into a high content or throughput screen in order to and there was a dress or there was asking the previous talk as well?",
            "So how do I actually design which compounds to test?",
            "Chemical space is huge, it's maybe 10 to the 60 small molecules, so it last ways we can test tend to the 7:00 or if you have DNA encoded libraries maybe 10 to the 9:00 or so, but there's a huge gap to the molecules you can make and that's the problem.",
            "So what should we actually test?",
            "I can't really give an answer, but I will outline some of the questions."
        ],
        [
            "One should think about.",
            "Yeah, so drunk relevant chemical space.",
            "So the question is what?",
            "What's the small molecule space that is actually relevant for drug discovery and in some sense no one really knows becausw.",
            "Historically, pharma companies worked on GPRS kinases.",
            "Now epigenetics targets for example and so that is driven by the chemistry that was active on historical targets.",
            "But we don't really know what future target classes are.",
            "So what's the chemistry we need in the future that's difficult to answer, but there are two other proxy questions we can ask.",
            "One is which proteins are actually current drug targets and the other question is which proteins can actually be modulated by small molecules.",
            "OK, because if you want to develop a drug, they usually those questions.",
            "What's the protein that's involved in a disease can modulate that protein to go back to the healthy state?",
            "And what is the chemistry?",
            "I need OK, and if you have a drug that usually needs to be somewhere in the area where those questions overlap and these questions I can answer based on data."
        ],
        [
            "And so there was one paper.",
            "It's very much worth read this sentence paper from two years ago where they looked into currently marketed drugs and their drug targets.",
            "That's a follow up of a paper of a previous paper, but on operating and so on.",
            "He wasn't from this work as well from years before, and it was actually quite a problem to compile.",
            "What are the structures and the targets of currently marketed drugs?",
            "Because they're different organizations that can approve drugs, so the MA here, the FDA, Japan's different system as well, but it's difficult to get a historical list of all the drugs that are approved in the different.",
            "A systems, so some people come up with a list of after 6000 or so drugs.",
            "But in this particular case it was about 1400 unique small molecule drugs and it was found.",
            "And this is actually the shocking number if you wish so that they target only 600 or so of human proteins.",
            "So it's a very small protein space that is targeted by current rocks and that is one of the effects of this me too approach.",
            "Everyone focuses on the same thing, jumps on the same train, basically serve similar chemistry and similar proteins.",
            "That people work on.",
            "So that's quite a small number here, and probably this number here of.",
            "So that's the small molecule drug targets.",
            "Biologic drug targets that will probably change and was also changing.",
            "Of course, is different ways of treating disease historically had small molecules that interact with the protein.",
            "Now you can also degrade proteins, for example, so if the same target, but you don't limit your degrade the whole protein.",
            "So with projects, so this is for example happening now, so there's much more biologics coming.",
            "Obviously the biggest selling drug right now by market values are biological right now.",
            "But the point here is you have a quite a small number of proteins that are targeted by current drugs."
        ],
        [
            "And the other aspect is that also changes overtime.",
            "So historically if you look back 2030 years, there was quite a lot of the PCR drug discovery being done, which means that many of the screening libraries you haven't pharma companies, they were designed for GPC ours, but they actually stayed on and on and they were library enhancement initiatives and so on.",
            "But you have much chemistry that comes from historical programs, so you have a GP CR drug discovery still happening right now, but headed speak properly.",
            "Years ago, so now then there was quite a lot of focus on kinases.",
            "That was first to debate whether you can target it because the ATP binding site is so similar, but that works because you can.",
            "You can bind to allosteric sites and so on, and of course right now we have the air of epigenetics targets for example.",
            "So proteins that read or write DNA modifications and so this also changes the desired chemical space.",
            "So the point here is if you want to design A screening library quite a lot of that information comes from historical projects.",
            "And that might not apply to a new project, and so you see the drugs that are approved on the market and so that so it's that why.",
            "Here's a color coded by by decade or five year intervals actually.",
            "And so you see quite a lot of the PCR drugs there, actually more than 30 years or so old and many of the kinase drugs were actually proved quite recently since 2011, so that changes.",
            "That indicates this changing shift in drug discovery.",
            "And that means that the chemical space we need in order to target those.",
            "Are proteins changes as well and the question is what is the chemical space we might need in the future to modulate biology?",
            "If you want to modulate the pathway, we don't know the target, so how should we design A screening library that's not trivial?",
            "Of course, if we know only what's the bioactivity matter by active meter that binds to particular major target classes."
        ],
        [
            "And one of the interesting findings from that paper is kind of a side note here in the context of the talk, but that's sometimes you have biological experiments that give you drivers of disease, for example from knockouts or knockdowns, and so on.",
            "And then the question is, can actually target something in that environment that changes the disease phenotype back to healthy and quite often that's not the case.",
            "So this figure comes from that paper as well.",
            "So what they looked at is the number of cancer drug targets.",
            "So 150, four counts and rocks.",
            "Out of which 85 are targeted agents, someone specific so you cytotoxic agents for example, and there are 553 cancer gene products that drive disease and only 30 or so actually overlap between both spaces.",
            "In this quite often means that if you have a loss of function mutation for example, you can of course not target the gene in order to gain function again.",
            "Yeah, so genetic experiments to find phenotypes or something quite different from small molecule modulators.",
            "So it's quite a different question.",
            "So it can target something in the network neighborhood maybe."
        ],
        [
            "And so this is about current drug targets.",
            "So the point is, an current chemical space that targets proteins isn't quite a narrow area of protein space in chemical space.",
            "That's the key message here.",
            "And then there was another study by Tutor Oprea, and so he looked up what is actually the again the protein space that is targeted by current drugs.",
            "But he also asked the question what are additional proteins where we either have ligands or we know something about biological function.",
            "So what are the easy next areas to step into if you wish?",
            "So he classified protein targets into 4 four categories.",
            "One was teklin, so that's clinical proteins.",
            "So these are the ones that are linked to current drug activity of drugs on the market.",
            "The next one is tkam, so these are proteins where we know ligands at different activity cut offs because there's different activity classes, so we have different infinities of binding and so on, and so these are proteins where we have legions but which are don't have a clinical compound, for example, and then the third category is T bio.",
            "So these are proteins which have a confirmed link to a disease but not necessarily ligand and the 4th category.",
            "These are the proteins or genes and proteins.",
            "But we don't know much about their function, and the idea was to investigate which fraction of all protein space is actually currently targeted.",
            "Where do we have ligands?",
            "Where do we know something about biological function and were don't we have any clue?",
            "M and the key message."
        ],
        [
            "So that paper is probably this figure here.",
            "So what you see here is here in the inner circle is 4 different categories, so these are the clinical drugs.",
            "A clinical proteins.",
            "These are the proteins which have a chemical ligand, the ones that are linked to biological function and the ones where we don't know anything.",
            "And the point is that the drugs we have currently on the market, they only target about 3% or so of the proteome that we know right now, and so that's that's a tiny fraction.",
            "And the proteins where we have ligands, Ohio.",
            "Compounds and this at least twice as much as it currently targeted.",
            "Proteome of all drugs.",
            "OK, so here we know ligands and for about half or so for proteins and we have some function or disease links.",
            "OK, so the point here is current drug discovery.",
            "Again, it's focused on a tiny fraction of protein space in many other cases we have ligands.",
            "Or we know something about biological function.",
            "So it would be beneficial to focus some of the efforts on those further protein spaces where we have some information already.",
            "It might be easier to discover new."
        ],
        [
            "Box.",
            "An and one of those.",
            "That's a different way to plot related information, so these are proteins with disease associations.",
            "Anamim says 3000 proteins also, and these are the protein classes, and you see that in some areas GPC ours or nuclear hormone receptors.",
            "For example, we have quite a large fraction of that protein class that is exploited by current drugs, but in some other classes, so by definition, for example, often GPC ours, we know something about the biological function, but we don't know anything about ligands, but also in other classes.",
            "And quite often we know something about biological functions.",
            "Or we have chemical ligands but we don't have drugs on the market.",
            "OK, that is overall only the minority of all proteins, so again, there's quite a lot of focus on what has been established before already.",
            "So why do I talk about this?",
            "The point is, quite often if you design something novel, it needs to be based on what you know and what you know is quite bias and limited when it comes to chemical space that is used right now as well as protein space that is targeted.",
            "So someone comes with a completely new target class for example, and you have to design chemistry.",
            "That's a completely novel question.",
            "You cannot necessarily transfer to that new question, which has implications for library design for screening, for example."
        ],
        [
            "And an interesting part from the paper was also this one here, so that the rich get richer basically.",
            "So what you see here is the dark genome at the one with annotated biological function as well as chemical ligands and the blue one.",
            "That's the taek Lim.",
            "So that's the targets.",
            "The proteins that are linked to clinical drugs, and what you see is that of course, in literature.",
            "You see, there's most known about the protein targets with clinical compounds.",
            "That's the way we would expect it.",
            "But also, for example, when you look at grants.",
            "So current research, basically most of that research is done on those targets as well.",
            "So it's basically where you have lots of information already.",
            "There's more literature, so if you write a grant application, you have more success rate because there's a good reason to work in that area.",
            "But that's the problem, right?",
            "You cannot discover much that is new, and so there's a.",
            "There's a certain trend to also stay in the areas that are known already.",
            "OK, so."
        ],
        [
            "To summarize that part, So what is the current rocked and druggable protein space?",
            "So drug discovery quite often tends to follow past successes, and that's true for protein space as well as chemical space.",
            "So current drugs are focused on quite a small number of proteins, but I think there's some information in those databases and there was actually a big U project.",
            "It's in the forest portal at the NIH that your work done.",
            "So all that information can be accessed online.",
            "In many cases, disease connection in small molecule ligands are known, so it should be quite easy based on currently existing information.",
            "To match the two better, so to move and to exploit this T bio antique M space.",
            "So sometimes the question right now is do we need novel chemistry or new modalities to target new targets?",
            "Well, that's difficult to say because of the completely new question.",
            "It might be likely, and there are quite a lot of fused by politics, for example and so on.",
            "Micro cycles that are coming up.",
            "But even the current proteome where we have ligands and that is unknown."
        ],
        [
            "Not as well.",
            "And yesterday there was a comment that we want to have selective ligands in order to decrease the number of side effects and also went through that paper again yesterday and there was a presentation actually of Cura yesterday, so he was looking into the question of whether that's really true.",
            "If you have a selective ligand, are you more likely to see fewer side effects?",
            "So is promiscuity correlated to the number of side effects?",
            "And that's actually not really the case.",
            "So what you have here is the number of targets annotated per drug from one 200 or so.",
            "And the number of adverse events per drug, so it's on a log scale in two year few targets, bedrock here 100 and you might see a trend, but of course it's difficult to estimate the density here.",
            "I don't know if the underlying data cannot, so cannot really say, but what you see is that in many cases even word ruckus only with single target you can see a huge number of side effects as well, so that's a it's a difficult question to answer, but if you have a more selective compound, are less likely to see side effects in the end because of course you have on target related side effects as well.",
            "So it's difficult to say.",
            "Some people argue if you modulate in network and multiple notes, you're actually less likely to see side effects.",
            "Depends on the case."
        ],
        [
            "So this was the protein part biological part.",
            "So the point is quite a lot of bioactivity in large we have right now is focused on few proteins, is quite biased and repetitive.",
            "And then there's a question of course.",
            "Do we also need to look into other drug properties that are relevant?",
            "And there was this Lipinski paper, some of you might be aware of.",
            "It's now 20 years or 22 years old, so he said he came up with those drug like properties.",
            "It's a concept or term that has been used in the wrong context sometimes, so that's only referring to.",
            "Orally absorbed crux.",
            "So companies will take orally is only true for 90% of the cases and not for those cases we have active transport.",
            "So vitamins for example steroids, they regularly violate the rule of five, but they are still actively transported for example, and so there's no problem with that.",
            "But in any case that was the rule, so you have particular physical chemical properties that might be relevant for library designer picking compounds, so such as lipophilicity, it tells you whether compound goes through a membrane.",
            "So that's important.",
            "Of course, if you have a phenotypic screen as well.",
            "So if you have good balance between solubility and permeability, molecular weight and hydrogen bond donors and accept US and OK.",
            "But that was the Lipinski rules and there was this recent follow up paper which actually checked does what Lipinski says is that supported by data and so historically this Lipinski rule did apply so many of the FDA approved or rocks they were fulfilling the Lipinski rules that are listed above here as well."
        ],
        [
            "Actually the whole the whole day to the properties of drugs that were approved, they changed my laundry here.",
            "So here you see the distribution of properties only molecular weight historically up to 97.",
            "It's up to the Lipinski paper and you see that 90% of drugs were actually below molecular weight of 500.",
            "So that's the blue part.",
            "But if you go into the last 20 years, you see that you have quite a large number of compounds that are above this particular cut off.",
            "OK, so basically it can be very dangerous to take historical data, make a rule of that, and think that's generally valid concept.",
            "It's only biased by what people have done so far, and so apparently there's quite a this different chemical space you can use as well in screens and later on drugs.",
            "Which can be kind of working there."
        ],
        [
            "Clinic and there's even an anti correlation.",
            "I found that quite interesting to see, so that's the number of new chemical entities.",
            "So new drugs on the market basically over the last 100 years or so or 70 years and you see that in the last 10 years there was quite an increase of the number of drugs approved, but if you correlate that to the."
        ],
        [
            "Molecular weight ranges and so this one here is below 500.",
            "The red part is above 500.",
            "You see that there actually anticorrelated, so you have more drug approvals, but at the same time drugs gets heavier.",
            "OK, so it's dangerous to use concepts such as Lipinski concept to design libraries.",
            "You have to be very careful."
        ],
        [
            "But of course they are solubility or her requirements, and that's if you have bioactivity data.",
            "What people routinely don't do, and also we have that property and Campbell or in public databases quite alot, don't check the solubility of a compound.",
            "So get a bioactivity.",
            "You didn't shake solubility, so your data is wrong basically.",
            "So what's the point here?",
            "First part?",
            "So the currently drugged proteome and requirements for chemistry, so there's a huge bias of research efforts in a minority of proteins between oh ligands form anymore and targets of interest and chemical space considered to be relevant, they change.",
            "So concept of which chemical space to actually need to design my library.",
            "That's a tricky concept because the knowledge that we have that is changing overtime the proteins that we need to target so we can use that data, but it certainly doesn't predict everything for future targets that we want to modulate as well.",
            "So and then there are two parts to a virtual screening as well as libraries on.",
            "So what does virtual screening refer to?",
            "So that's the starting point.",
            "In case negative molecule is known and there are two parts in here is how can I describe molecules and how can I calculate similarities between molecules?",
            "It seems like a trivial concept and in some sense the idea is trivial, but similarity is one of those birds that humans use.",
            "That means everything and nothing because it depends on how you perceive similarity.",
            "How do you put it in?"
        ],
        [
            "So descriptor space."
        ],
        [
            "So let's see what we can do here.",
            "So virtual screening and similarity searching.",
            "So if you compare two molecules, ligand based similarity searching is basically the same as virtual screening, and it's quite often employed when no target structure is known.",
            "Of course you can do docking, but scoring functions are not really good enough in many cases.",
            "So many cases you can do a similarity search to come up with GNU Bio active."
        ],
        [
            "Chemical matter, and that's based on one core assumption, and that's the assumption of all computer aided drug discovery basically, and that is the assumption that similar molecules have similar properties, and that seems like a trivial statement as well.",
            "When I was doing my postdoc at Novartis, we sometimes joke that we need to write a follow up paper to this molecular similarity principle, and there's the molecular weight principle, so larger molecules are heavier.",
            "We didn't publish that yet, but the question is, how do we actually describe similarity of molecules?",
            "Humans are very good at perceiving similarity.",
            "But the question is, how do you make that explicit to computer?",
            "Sometimes you can learn it from the data, but often you don't have enough data and then you need to make an explicit definition of descriptors.",
            "For example and you need 2 steps for that.",
            "So the first one is molecular representation and the second one is a similarity or distance measure of two molecules."
        ],
        [
            "M and virtual screening in some sense is kind of a schizophrenic exercise because what we hope is that the property of interest remains.",
            "So if one active molecule research database I found another active molecule, but other properties change, so we want to go to different chemical space that is better soluble, less metabolically labile, and so on.",
            "And what do you assume?",
            "And that's very important.",
            "Here is a somewhat smooth activity landscape, so here's for example.",
            "Here are descriptor axis.",
            "So this is meant to be a plot of chemical space.",
            "And if by activity of a random by activity here on the other axis, and you see that if peaks here sober by activity changes quite abruptly.",
            "But you have other areas, I think here with the landscape is much more smooth.",
            "But the problem here is chemical space is not 2 dimensional or three dimensional, it's whatever 100 dimensional.",
            "So so in that causes problems for diversity selection as well As for plots like that.",
            "So never believe a plot where plot molecular structures in 2D for similarity.",
            "If you look at neighboring molecules they virtually never.",
            "Look similar, but this is the assumption here, so we need to have some smoothness in the activity landscape so similar molecules have some kind of similar."
        ],
        [
            "Properties then you.",
            "So if you have a query structure you're representing molecules in a descriptor space quite often in a binary bit string, and then.",
            "So this is the first question, how do you get here?",
            "And then you compare the molecule to others.",
            "So in this case those three molecules have a similar property to this one, they inhibit anger tensin converting enzyme, but they're not obviously structurally similar.",
            "So the question is so versus similarity in here.",
            "And if you have a chemist or look at patterns here you see if they might bonds for example in those molecules.",
            "So there are some underlying patterns that are similar, but we need to have a proper representation too."
        ],
        [
            "Exploit that in practice.",
            "So what does it look like in practice?",
            "Similarity searching so you have one compound you use it to rank.",
            "Usually a whole database, so it can be virtual molecules as well there.",
            "Now companies like Enamine for example awaken by 100 million or so molecules for $10.",
            "Sorry, $400 or so piece so you can scan that quite quickly, efficiently, computationally.",
            "What do you assume is that if your query is active against your enzyme or receptor your target, then the assumption is that the most similar compounds are also active against that protein.",
            "Assuming that representation and similarity measure works."
        ],
        [
            "So what you want to go from is so this is the list of our molecules in your database.",
            "The red lines are the active compounds.",
            "Usually they are randomly distributed, but if you sort them according to similarity to a query which is active, you have an enrichment of molecules at the top.",
            "Yeah."
        ],
        [
            "Among the most similar molecules, and then, as I think know you mentioned yesterday already, you can see among the, let's say, 10% of the most similar molecules, 60% of active source are found, and then you can calculate an enrichment if you wanted to get there earlier as well.",
            "But the question is what does that number really tell me?",
            "It tells me something.",
            "It tells me how many of those molecules are active, but that's not the only thing I want because."
        ],
        [
            "Of course, what I want is also some novelty.",
            "I don't always want to find the same molecule, so you also need to see to have some kind of novelty measure and quite often, but it can count as how many different schedules do you find, but for practical purposes you would ideally like to do parallel prospective validation, so you have five different methods.",
            "You test 10,000 compounds and you see what are your hit rates.",
            "Ideally you would like to do that, but practically you need to do it on historical data and that's the problem.",
            "Again, with those biases you have quite a lot of analogs in your databases.",
            "So you need to do clustering.",
            "For example is no illustrated.",
            "You need to cluster your compounds.",
            "That is one option.",
            "You can also do time split validation so and that's some companies like that because that's in their view most predicted for novel project.",
            "So can I predict for the next project.",
            "In my opinion time is not the variable to consider the clustering, I prefer because the question is whole novel is my chemistry is but at times with validation is another option to do as well."
        ],
        [
            "Then there's one big difficulty with validations, and that's always the question.",
            "Does your model actually learn the property of interest?",
            "And sometimes that's not the case, because you can get spurious correlations, and so for example, if you're modeling activity in a cellular essay.",
            "So let's say so from a high content screen.",
            "Do you actually model activity against the pathway?",
            "Or you do have a kind of confounding factors such as permeability?",
            "So do you model actually permeability of your company as a confounding factor?",
            "Or if you're small compound sets, so let's for example one.",
            "Project we worked on recently.",
            "So can you classify compounds that are cause drug induced liver injury?",
            "We have only a few hundred data points and then the question is if you have two classes.",
            "I actually modeling delete so active and inactive, toxic and non toxic or do you model a different distribution?",
            "Let's say of ATC codes if you have different types of compounds with different bioactivity classes in one side versus the other, maybe that's what your model and that can easily be the case if you model by activities that you actually model, you're a correlated.",
            "Variables with your."
        ],
        [
            "Property of interest that happens very often.",
            "OK, so in the first step you need to describe your molecules in some way and there's no natural way to describe chemistry because always there different aspects of chemical structure that matter and there only three examples here.",
            "So sometimes if you model toxicity, for example is reactivity that met us, so the particular functional group.",
            "Can.",
            "My Groupon ago particular chemical reaction.",
            "Sometimes it's the surface, for example, for ligand protein directions, sometimes is the physical chemical property for permeability of solubility, and that is something.",
            "You would probably like to make explicit to the model before hand that some argument that we can learn from the data, probably with an ideal infinitely large, dare say you probably could, but quite often in practice we don't have that and there's no start, not end of the molecule.",
            "So the question is, how do we actually encode 3D information?",
            "We have confirmation of flexibility, different protein."
        ],
        [
            "States and so on.",
            "So this is a slight I was always including to illustrate how do we actually make explicit to the computer to recognize objects?",
            "And there's now in the last five years or so there was of course quite a progress when it comes to convolutional networks and so on.",
            "So part of that you can probably learn from the images about humans actually have very good at generalizing from images, so these are all Tracy obviously, but they have quite different shapes in different colors.",
            "And some of them don't even have leaf sensor on, so they're quite away quite far away from your examples from the training set if you wish so many cases, I believe, especially in their life Sciences, what we need is combination, such as we've seen the Macau Macau algorithm as well a combination of some type of tight information or prior knowledge.",
            "Whatever you want to call that, as well as data from the models.",
            "So, for example, if you learn here, the tree consists of the trunk, and if you recognize the trunk that's in part of the tree, you can have some kind of structured model.",
            "And probably that would help in areas, especially where we don't have enough data, so humans are good at recognizing patterns, but computers are some."
        ],
        [
            "Times and not that good either.",
            "So how can we classify how can we describe molecules to the computer?",
            "So this is kind of a standard way to classify descriptors so we can have different dimensionalities of of molecules of descriptors.",
            "So some of molecular weight, some are fragments.",
            "Then we have three descriptors.",
            "We could include confirmations.",
            "You can also do and that was at least two or three papers.",
            "Right now you can separate represent the molecule as a 2D drawing represented in different orientations if you wish, put that into a network and then actually those representations.",
            "Surprisingly to me as well perform about on par with Morgan finger circular fingerprints and so that is quite surprising to me because Morgan fingerprints were quite for quite a long time 10 or 15 years.",
            "The benchmark be CFP fingerprints for example.",
            "They're still quick to calculate.",
            "There are many advantages in practice, but still from images you actually get quite a lot of information as well.",
            "There was this toxic colors, I think.",
            "Paper and we."
        ],
        [
            "Publishing is about recently.",
            "So why should we actually use what sounds very simple descriptors?",
            "1 dimensional descriptors and they tell us quite a lot about particular relevant properties of molecules.",
            "Even if you have a simple descriptors such as lock P. So that tells you how lipophilic is, your compound doesn't stay in water or lipophilic environment.",
            "That tells us quite a lot about whether common gets through membranes.",
            "For example, for practical purposes, that's hugely relevant.",
            "So basically, if you build a bioactivity model and you have a deep learning model or random forests or so always.",
            "Do some reality check.",
            "How does my baseline model behave so you can scramble your model, but it can also say how good is my model if I just use log P as a single descriptor or very limited set of descriptors, simply to see if there's some very simple trivial correlation in your data set that you can pick up."
        ],
        [
            "You can use 2D descriptors as well, and quite often they're fragment based or fingerprints.",
            "For example.",
            "They work very well, they are quick to calculate, so you can calculate circular fingerprints for about 10,000 molecules a second or so."
        ],
        [
            "It's probably even more.",
            "Yeah, disrupt him yesterday already so you look at every heavy Atom in the next layout, the next layer, and so that seems to be the right level of abstraction."
        ],
        [
            "The molecule is interesting that some molecular descriptors actually reused for purpose.",
            "They were not intended to be used for, and they perform remarkably well, and one of those examples is MDL keys, which you might have come across already, so they were actually invented in the 80s or so in order to speed up searches, I mean, their computational power was huge problem.",
            "So the question was, how can I find all molecules that have particular functional groups?",
            "So that's a it's a key set, so it's a bit string, basically of 166 bits.",
            "So it's relatively limited.",
            "There's a longer one as well, and there's very simple definitions.",
            "So does my molecule contain a heteroatom?",
            "Doesn't have a carbon and CC double bond, and so on.",
            "And this is actually it was used for cataloging chemical information.",
            "More recently, people have used it for classification and so on as well, and there seems to work remarkably well or they they are very coarse grained as so many areas that program not sufficient.",
            "But in some areas you can use very descriptors that have been used for every section or descriptive features.",
            "Key sets that were used for one particular purpose, and you can use them even for similarity searching and so on.",
            "In many cases you get good results with that, although you shouldn't in theory."
        ],
        [
            "And three dimensional descriptors in theory, should perform better because you are looking at hysterical spatial information of features in the molecule.",
            "But in practice, in my experience that's quite often does not lead to superior results because you have conformational flexibility, so you increase computational cost.",
            "I don't know 100 fold or even 1000 fold in some cases, but that doesn't give you much more information.",
            "So in my experience, that is in many cases."
        ],
        [
            "Not a good trade off, but what you can do is you can use pharmacophore IK descriptors for example so they are quick to calculate.",
            "So you simply calculate properties and distances of atoms in a molecule and you put that into a bit string.",
            "So that gives you a short representation.",
            "Avail away again, which you can use for similarity searching.",
            "So in practice that can be a very diverse, very popular 15 years ago or so.",
            "In order to search large chemical databases, and in order to a particular go to novel scaffolds as well, because that's what you want, right?",
            "So you want to have a similar.",
            "Arrangement of features that give you activity but different underlying kemmis."
        ],
        [
            "So why can conformational space actually be tricky?",
            "So that's a short molecular dynamics.",
            "Simulation of this anger tends in converting enzyme inhibitor, and there are some distances distance distributions market here.",
            "So the distance of that carbon to this carboxylic acid for example.",
            "And if you observe that molecule in solution and it wiggles around what you see is that this distance can be anywhere between 18 angstroms and seven angstroms or so.",
            "OK, so many molecules are hugely flexible and this illustrates one of the problems by using 3D information can be really tricky.",
            "If you include molecules for the computer."
        ],
        [
            "Descriptors all behave differently, and that can be quite a problem.",
            "So you have two molecules.",
            "I guess it's a.",
            "Do you have two molecules, so this particular query structure and this target structure and the question is, are those two molecules similar and even if you're not a clemency will probably say OK, they look quite different quite apparently, but if you use different types of descriptors, for example type Tatum, triangles, type graph triangles and so on, they actually rank those molecules.",
            "The similarity of those molecules.",
            "At position 7 or 23 out of 1000 pounds, they are compared to and so that means that those descriptors perceive those molecules as pretty similar.",
            "OK, and that's not what agrees with intuition.",
            "OK, so not every molecular similarity or distance measure would agree with what you would expect to him.",
            "On the other hand, if you look into shape based descriptors, for example as you would expect, the shape of those two entities is entirely distinct, so they are here.",
            "The similarities ranked very low.",
            "And let's say in case you lose molecular descriptors and you are concerned about the behavior and that's one of the papers you might want to look up.",
            "So that gives some illustrations.",
            "Also, if you have a CFP for fingerprints, for example, what they don't consider as was alluded to in the morning hysteric chemistry.",
            "But another thing is repeat units, for example.",
            "So you have features.",
            "If they are there once or 20 times, the descriptor doesn't care, which means you can have a much larger molecule that sets the same features, and those molecules are then perceived as similar.",
            "Although they aren't, if you have much larger molecule, doesn't fit into the binding sites, quite a different molecule.",
            "So EC FP fingerprints have this sensitivity as well as terpenes for example, so other types of repeat units in natural products that they don't pick that up as well.",
            "So every descriptor some kind of weaknesses."
        ],
        [
            "Yeah, so representation is one step, then the comparison of the molecules is the next one here.",
            "Would like to point out simply, there are three different ways to measure similarity or dissimilarity, and I would like to point out the difference between similarity distance and dissimilarity because the."
        ],
        [
            "It is not as trivial as it might sound.",
            "So if you compare molecules, usually body uses similarity coefficients and there's one coefficient that is used quite a lot.",
            "That's attorney model coefficient, so you simply calculating how many bits are in common and you divide that by the number of bits that are set in either of the particular fingerprint bit strings.",
            "So here's an example.",
            "6 bits.",
            "You have.",
            "The 1st three are set, those ones are not.",
            "Here it's a different pattern, and the first and third degree, so the similarities 2.",
            "/ 5 So .4.",
            "So this descriptor.",
            "This similarity coefficient then calculates similarity between those two molecules and and that's important.",
            "It considers both features in common and not uncommon, and that is that is."
        ],
        [
            "Quite a different behavior from some other coefficients.",
            "You can calculate an.",
            "There's this illustration here, so table and an elephant are similar according to distance coefficient, because both cannot fly OK, because if you use the descriptors base of is that object able to fly, and that is not the case in both cases.",
            "Then the distance is 0, so this particular representation assigns the distance to zero, which you might misinterpret as a similarity of 1 between two objects.",
            "OK, so the point here is that similarity coefficients and distance coefficients as something completely different, and that's numerically illustrated here.",
            "So if you have two bit strings of five bits each and in one case for bids are set here, 5 bits are set, your similarity would be .8 and your distance is 1.",
            "So one bit is different and the same distance would be achieved in this particular case.",
            "But so the distance is 1, one bit is different again, but that any model coefficients or the similarity would be hugely different OK, and so you have to be careful with those terms similarity and distance and dissimilarity as we see on the next slide.",
            "They mean something quite different and often similarity coefficients behave more.",
            "In line with what might be expected psychologically, they're actually interesting papers of Twersky in the 70s and 80s who looked into how humans perceive similarity, and this is actually where much of the similarity between molecules was based on almost whiskey."
        ],
        [
            "And is this the similarity actually the opposite of similarity?",
            "That's what you might assume, because formerly, you could say this similarity could be seen as one over similarity of 1 minus similarity, but in practice that's quite often not the case, because if you have a bit string and you have a number of features that agrees between particular objects, that is a much higher resolution in the near similarity range.",
            "OK, if basically nothing agrees, you don't have a resolution anymore now, so similarity is formally.",
            "If you wish is the opposite of dissimilarity, but because of the way how similarity is defined, you have a much better resolution in the similarity arrange so you cannot say much about objects that are very far away.",
            "There is implications for diversity selection of compounds, so don't just use Tanimoto coefficient which is defined for similarity and expected to Topeka properly diverse set."
        ],
        [
            "And yeah, its shape is important and similarity can be very misleading because sometimes very small changes and similarity kind of huge effect is for example here the molecule.",
            "And if that our group is methyl or so.",
            "In this case it would be a caffeine if there's a methyl group here, and if there's a hydrogen, it's a different molecule and you see a 10,000 fold difference in activity.",
            "OK, so similarity is a global property, sometimes local small differences matter and that can be difficult to.",
            "Pick up."
        ],
        [
            "And so similarity is not an intrinsic property of objects, and so it depends on the context.",
            "So in some sense, that's why the question how similar to molecules is quite meaningless, because it depends on the question with respect to which property and molecular weight or by activity were one particular feature might matter.",
            "So it always depends on the context and it's difficult to define quite often need to define that empirically, and quite often what is useful instead of using the external reference frame if you simply say how similar to molecules.",
            "In the absence of any information, if you want to do ever quick and dirty solution, you can use similarity of fingerprints of course, but it's better if you have some external reference frame that tells you which similarity matters."
        ],
        [
            "More than others in a given context, and what recently came up because we have more and more data is for example, that you use HTS fingerprints or docking based fingerprints or predicted targets or gene expression data and so on in order to define bioactivity profiles of molecules, because that defines the output of the system.",
            "So you put a molecule into your system system response.",
            "The same, although we have different compound, then the similarity is high, although the chemistry is quite dissimilar OK, the model response in a similar way, on the other hand.",
            "If you look into if you have very similar compounds, you still get a different readout because you hit a different target, so then that readout similarity might not be very high.",
            "So basically it depends on the response of the system on the external context on what you care about, so you have those HTS fingerprints based on pub chem essays.",
            "For example, people at Russian Novartis did that.",
            "Other companies as well.",
            "We did that on predicted target based affinity fingerprints, predicted bioactivity profiles, and that representation is probably if you have enough data.",
            "And that's a very good representation to use in my opinion.",
            "So is it possible and sensible to?"
        ],
        [
            "Define molecular similarity, yeah, but you need to be careful.",
            "So it depends on the context.",
            "So if you have a context and you can define that is good to use that context, do I care about up and down regulation of that pathway?",
            "Then that's a much much better readout to use than simply using fingerprints as a distance or similarity measure.",
            "So choose a meaningful representation of similarity measure depending on their purpose.",
            "OK, so."
        ],
        [
            "Finally, so how would we design A screening library?",
            "For example, for high content screens?",
            "So the question is to have a manageable selection of some molecules for testing.",
            "Manageable can be reasonably small, can be 10,000 molecules or so, sometimes even smaller because they have more complex essays than high throughput screening where it has up to a million or so you want to have a reasonable starting point for drug discovery, so you want to have good hit rates, but good means not too high and not too low, so something should hit, but if everything hits is also not a good starting point.",
            "Suitable chemistry.",
            "So it should be chemistry that soluble suitable for skin properties and so on.",
            "And there are two aspects.",
            "One question is, what's the space to sample from and how to sample from that space?"
        ],
        [
            "And one point here is, chemical space is not equal, so we had the biases in the data we heard about in the first part of the talk.",
            "So we have much more data on historical protein targets.",
            "For example, more explored chemical space.",
            "I mean, if people for example establish synthetic routes, then those get over and over exploited.",
            "So you have much more compounds in.",
            "Collections which you can purchase from you have more Campbell data, so all that leads to bias and but there's also possibly something intrinsic and chemical space.",
            "There were certain parts of chemical space are more likely to hit than others.",
            "There was this paper for example, also from group at Novartis that looked at dark chemical meta.",
            "So that means you have a compound collection.",
            "In this case, let's say a million compounds or so, and they are tested in essays and so you do that a few dozen times a year or so in a large company, and they looked into compounds that were inactive in more than 100 essays.",
            "So usually compounds would be expected.",
            "You can do some permutation tests to be active after a certain number of screens, so it's very unusual for compounds not to be active after 100 screens or so, and what you see is that actually properties are pretty similar between compounds that do hit and compounds that don't hit the question is, is there something intrinsic to the chemistry and that appears to be because they actually two ends of the spectrum?",
            "One is very promiscuous, compounds compounds that bind to a large number of targets.",
            "Many kinase inhibitors, TCR ligands and so on.",
            "But you also have components that are hardly ever active and so the question is how to actually assemble the screening library in order to achieve a good balance between sampling chemical space and also achieving a suitable hit rates or not composite active to off."
        ],
        [
            "And it's quite a number of different properties he would need to consider.",
            "Some of them are probably more relevant in earlier stages than if you go into the clinic.",
            "You don't really consider that early anyway, so you want to have components that are active but not too often that certainly a soluble enough that's effective.",
            "That's often a confounding factor in experimental bioactivity data and compounds that are not obviously toxic because they would they would mess up your essay system as well.",
            "And then of course you would you consider other practical factors at some stage is Tacoma synthesizer.",
            "Lost and so on.",
            "Can I patent it?"
        ],
        [
            "Representation matters, that's one part.",
            "That's the part we partially covered before already, so we can use a chemical representation.",
            "We can also go into shape.",
            "So for example, there was a publication on the Pocket pocket home by rumor began 10 years ago or so.",
            "So the question is, if you want to target all protein binding pockets.",
            "So any kind of shape and direction properties you can enumerate the poker Dome and then you can use that for example to assemble a fragment based screening library or small molecule screening library in order to sample that diversity in order to theoretically target.",
            "Every type of protein that is present in the poker tone.",
            "You can also look into substructural diversity, so we have different ring systems.",
            "Different schedules in there and or using functional diversity based on readouts.",
            "But of course that is limited by the readouts you use, for example by the proteins you can currently target.",
            "OK, so this is by us again that I."
        ],
        [
            "Alluded to in the beginning.",
            "So this representation aspect, probably functional readouts, is a good choice.",
            "And then there's the question how to pick compounds and that can be very tricky because if you go for overall maximum diversity, if you visualize chemical space at the borders, you basically only find rubbish.",
            "You find a very unusual compounds if you do that with pubchem, for example, and you're looking for compound paths with maximum distance, low similarity, and then you find chemistry you wouldn't like to screen for, so you probably would have some kind of maximum optimization, or your classifier compounds.",
            "So you want to maximize the minimum distance between compounds."
        ],
        [
            "But there's also conceptual problem actually.",
            "With a diversity selection of compounds and the question is can we actually pick a representative subset.",
            "And I would say, and there's some papers that argue that as well, that's actually conceptually not really possible.",
            "Of course we can pick diverse compounds, but can we really handle that high dimensional space?",
            "So we operate in a very high dimensional space, say it's 100 dimensional, few 100 dimensional.",
            "No one can really say well there is.",
            "This is chemical space.",
            "Quite tricky is very high dimensional.",
            "You cannot project it onto D and do proper selection and so if the bioactivity landscape is very smooth, we could probably pick.",
            "Representative examples, but only if the dimensionality is not high.",
            "But if we have if the impact of activity clips is profound, we can never expect to sample that space.",
            "OK, and because if you have a 900 dimensional space in your, changing some part of your molecule, change by activity, that's a huge space.",
            "You will not be able to and practice sample that space so you could for example, stay in quite a small area of chemical space and that would be as diverse as sampling from the much larger space.",
            "OK, because you have changes in bioactivity evening, that's more.",
            "Area of chemical space."
        ],
        [
            "There also some practical aspects, though if you want to assemble your screening library once that screens are not perfect, of course they're noisy.",
            "So if you want to learn about the activity of a compound quite often we would like to know about the confidence of that measurement.",
            "So you want to have, let's say 5 similar compounds or so.",
            "One scaffold near screening set, because then what you can do is you can see do actually get a similar response, not the same necessary, but a similar response, and you can also know bout the SARC around the molecule already, which gives you some starting points for optimization.",
            "It's not just that we want to diverse molecules, the question is also what can you use that information for.",
            "In practice, once you found some active molecules."
        ],
        [
            "What do you do empirically?",
            "And that's virtually all the big companies I think.",
            "I do that to some extent.",
            "Quite often have a small set of compounds that are more affection annotated.",
            "So Novartis 20 years ago.",
            "So it was called the climax box.",
            "It's probably called differently than other companies, so we have a set of a few 1000 up to 10,000 or so usually compounds that are mode of action known and annotated.",
            "So that's it.",
            "Drugs on the market quite often, but it can also be probe compounds.",
            "Because there's this drugs on the market don't need to be particularly selective.",
            "Probs need to be because we want to probe a pathway.",
            "Drug only needs to be safe in the clinic and that's a different question, so probably would rather put in more probes in this type of data set.",
            "Quite usually you would like to have multiple representatives from out of action, trust with different schedules so you can see is the effect scaffold related, or does it actually translate to different scaffolds that target the same protein and then you can have a set of 1000 or 10,000 or so of compounds that target different biological pathways and this is probably a good way.",
            "If you have a functional biological readout to assemble screening library, but this stays within well annotated chemical and bioactivity space again, so it goes back to the bias again, so we can only pick those compounds that are diverse in their bioactivity space.",
            "We know already which might be limiting for the future."
        ],
        [
            "So we need to so diversity library design.",
            "So we need to define what's relevant.",
            "Chemical space of interest, difficult to do.",
            "Looking forward with new targets, new areas of chemistry, but we don't have much information right now.",
            "We need to have some kind of descriptors and similarity measure can be based on chemistry or effects, ideally based on context.",
            "As I said, diversity selection, high dimensional space is not trivial at all.",
            "It's a it's huge dimensionality and still true dimensionality and the number of data points.",
            "If you can buy.",
            "Whatever 300 million compounds.",
            "Also from an.",
            "I mean we cannot just cluster that and pick cluster centers that can be difficult with that number of compounds.",
            "And, for example, annotated libraries might be a good starting point."
        ],
        [
            "Yeah, so to summarize.",
            "So drug discovery biology as well as chemistry in that area that's hugely biased from what you know in the past in protein space, but also chemical space.",
            "If a starting point is known, we can do virtual screening.",
            "Always pick a good descriptor as well as distance, measure an if no starting point is known we can design libraries for prospective screening and probably they should be based on some type of functional or bioactivity annotation.",
            "Now, thanks."
        ]
    ],
    "summarization": {
        "clip_0": {
            "is_summarization_sample": false,
            "summarization_data": [
                {
                    "sent": "So what I consider in this talk is the chemical space that we actually put into, for example, a high content screen or high throughput screen.",
                    "label": 0
                },
                {
                    "sent": "So the question is not what do I do with the read out?",
                    "label": 0
                },
                {
                    "sent": "The question is how to actually connect the chemistry.",
                    "label": 0
                },
                {
                    "sent": "I put it into the readout OK because there's obviously connection.",
                    "label": 0
                },
                {
                    "sent": "You cannot really understand what happens if you do not consider what is actually the driving factor behind it.",
                    "label": 0
                },
                {
                    "sent": "Change the phenotypic change for it.",
                    "label": 0
                }
            ]
        },
        "clip_1": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "And so there will be 3 three sections of this talk.",
                    "label": 0
                },
                {
                    "sent": "So the first one is in current drug discovery.",
                    "label": 0
                },
                {
                    "sent": "What I actually, the chemical space that is considered by current drugs on the market, and that can mean chemistry.",
                    "label": 0
                },
                {
                    "sent": "It can also mean bioactivity space, because in drug discovery, as you might have realized already.",
                    "label": 0
                },
                {
                    "sent": "But you will certainly see it after this talk.",
                    "label": 0
                },
                {
                    "sent": "There's quite a lot of metoo activity.",
                    "label": 0
                },
                {
                    "sent": "So historically, when one company developed a drug against the target six months later, there was another company coming up.",
                    "label": 0
                },
                {
                    "sent": "Trying to bust the patent, so just change the ring slightly and to have a meet two compound with no not many additional positive properties, but simply another component on the market.",
                    "label": 0
                },
                {
                    "sent": "So in drug discovery is quite driven by that, so everyone jumps on the same target there and that creates a problem.",
                    "label": 0
                },
                {
                    "sent": "Also from the Machine learning site.",
                    "label": 0
                },
                {
                    "sent": "For example, if you want to evaluate your methods and you do random validation for example, that doesn't always work because we have quite a lot of me two data points in most datasets, so I will.",
                    "label": 0
                },
                {
                    "sent": "I will cover that.",
                    "label": 0
                },
                {
                    "sent": "In the beginning and then there will be 2 topics and that's the actual topic of the title of the talk.",
                    "label": 0
                },
                {
                    "sent": "One is virtual screening, so if I have one combined with an activity, how can I pick another one in chemical space?",
                    "label": 1
                },
                {
                    "sent": "Usually that has similar activities and the other point is if I have no clue what to start with, how can I actually assemble a screening library?",
                    "label": 0
                },
                {
                    "sent": "So what are factors I need to consider that I can put into a high content or throughput screen in order to and there was a dress or there was asking the previous talk as well?",
                    "label": 0
                },
                {
                    "sent": "So how do I actually design which compounds to test?",
                    "label": 0
                },
                {
                    "sent": "Chemical space is huge, it's maybe 10 to the 60 small molecules, so it last ways we can test tend to the 7:00 or if you have DNA encoded libraries maybe 10 to the 9:00 or so, but there's a huge gap to the molecules you can make and that's the problem.",
                    "label": 0
                },
                {
                    "sent": "So what should we actually test?",
                    "label": 0
                },
                {
                    "sent": "I can't really give an answer, but I will outline some of the questions.",
                    "label": 0
                }
            ]
        },
        "clip_2": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "One should think about.",
                    "label": 0
                },
                {
                    "sent": "Yeah, so drunk relevant chemical space.",
                    "label": 1
                },
                {
                    "sent": "So the question is what?",
                    "label": 0
                },
                {
                    "sent": "What's the small molecule space that is actually relevant for drug discovery and in some sense no one really knows becausw.",
                    "label": 1
                },
                {
                    "sent": "Historically, pharma companies worked on GPRS kinases.",
                    "label": 0
                },
                {
                    "sent": "Now epigenetics targets for example and so that is driven by the chemistry that was active on historical targets.",
                    "label": 0
                },
                {
                    "sent": "But we don't really know what future target classes are.",
                    "label": 1
                },
                {
                    "sent": "So what's the chemistry we need in the future that's difficult to answer, but there are two other proxy questions we can ask.",
                    "label": 0
                },
                {
                    "sent": "One is which proteins are actually current drug targets and the other question is which proteins can actually be modulated by small molecules.",
                    "label": 1
                },
                {
                    "sent": "OK, because if you want to develop a drug, they usually those questions.",
                    "label": 0
                },
                {
                    "sent": "What's the protein that's involved in a disease can modulate that protein to go back to the healthy state?",
                    "label": 0
                },
                {
                    "sent": "And what is the chemistry?",
                    "label": 0
                },
                {
                    "sent": "I need OK, and if you have a drug that usually needs to be somewhere in the area where those questions overlap and these questions I can answer based on data.",
                    "label": 0
                }
            ]
        },
        "clip_3": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "And so there was one paper.",
                    "label": 0
                },
                {
                    "sent": "It's very much worth read this sentence paper from two years ago where they looked into currently marketed drugs and their drug targets.",
                    "label": 1
                },
                {
                    "sent": "That's a follow up of a paper of a previous paper, but on operating and so on.",
                    "label": 0
                },
                {
                    "sent": "He wasn't from this work as well from years before, and it was actually quite a problem to compile.",
                    "label": 0
                },
                {
                    "sent": "What are the structures and the targets of currently marketed drugs?",
                    "label": 0
                },
                {
                    "sent": "Because they're different organizations that can approve drugs, so the MA here, the FDA, Japan's different system as well, but it's difficult to get a historical list of all the drugs that are approved in the different.",
                    "label": 0
                },
                {
                    "sent": "A systems, so some people come up with a list of after 6000 or so drugs.",
                    "label": 0
                },
                {
                    "sent": "But in this particular case it was about 1400 unique small molecule drugs and it was found.",
                    "label": 0
                },
                {
                    "sent": "And this is actually the shocking number if you wish so that they target only 600 or so of human proteins.",
                    "label": 0
                },
                {
                    "sent": "So it's a very small protein space that is targeted by current rocks and that is one of the effects of this me too approach.",
                    "label": 0
                },
                {
                    "sent": "Everyone focuses on the same thing, jumps on the same train, basically serve similar chemistry and similar proteins.",
                    "label": 0
                },
                {
                    "sent": "That people work on.",
                    "label": 0
                },
                {
                    "sent": "So that's quite a small number here, and probably this number here of.",
                    "label": 0
                },
                {
                    "sent": "So that's the small molecule drug targets.",
                    "label": 0
                },
                {
                    "sent": "Biologic drug targets that will probably change and was also changing.",
                    "label": 0
                },
                {
                    "sent": "Of course, is different ways of treating disease historically had small molecules that interact with the protein.",
                    "label": 0
                },
                {
                    "sent": "Now you can also degrade proteins, for example, so if the same target, but you don't limit your degrade the whole protein.",
                    "label": 0
                },
                {
                    "sent": "So with projects, so this is for example happening now, so there's much more biologics coming.",
                    "label": 0
                },
                {
                    "sent": "Obviously the biggest selling drug right now by market values are biological right now.",
                    "label": 0
                },
                {
                    "sent": "But the point here is you have a quite a small number of proteins that are targeted by current drugs.",
                    "label": 0
                }
            ]
        },
        "clip_4": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "And the other aspect is that also changes overtime.",
                    "label": 0
                },
                {
                    "sent": "So historically if you look back 2030 years, there was quite a lot of the PCR drug discovery being done, which means that many of the screening libraries you haven't pharma companies, they were designed for GPC ours, but they actually stayed on and on and they were library enhancement initiatives and so on.",
                    "label": 0
                },
                {
                    "sent": "But you have much chemistry that comes from historical programs, so you have a GP CR drug discovery still happening right now, but headed speak properly.",
                    "label": 0
                },
                {
                    "sent": "Years ago, so now then there was quite a lot of focus on kinases.",
                    "label": 0
                },
                {
                    "sent": "That was first to debate whether you can target it because the ATP binding site is so similar, but that works because you can.",
                    "label": 0
                },
                {
                    "sent": "You can bind to allosteric sites and so on, and of course right now we have the air of epigenetics targets for example.",
                    "label": 0
                },
                {
                    "sent": "So proteins that read or write DNA modifications and so this also changes the desired chemical space.",
                    "label": 1
                },
                {
                    "sent": "So the point here is if you want to design A screening library quite a lot of that information comes from historical projects.",
                    "label": 0
                },
                {
                    "sent": "And that might not apply to a new project, and so you see the drugs that are approved on the market and so that so it's that why.",
                    "label": 0
                },
                {
                    "sent": "Here's a color coded by by decade or five year intervals actually.",
                    "label": 0
                },
                {
                    "sent": "And so you see quite a lot of the PCR drugs there, actually more than 30 years or so old and many of the kinase drugs were actually proved quite recently since 2011, so that changes.",
                    "label": 0
                },
                {
                    "sent": "That indicates this changing shift in drug discovery.",
                    "label": 0
                },
                {
                    "sent": "And that means that the chemical space we need in order to target those.",
                    "label": 0
                },
                {
                    "sent": "Are proteins changes as well and the question is what is the chemical space we might need in the future to modulate biology?",
                    "label": 0
                },
                {
                    "sent": "If you want to modulate the pathway, we don't know the target, so how should we design A screening library that's not trivial?",
                    "label": 0
                },
                {
                    "sent": "Of course, if we know only what's the bioactivity matter by active meter that binds to particular major target classes.",
                    "label": 0
                }
            ]
        },
        "clip_5": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "And one of the interesting findings from that paper is kind of a side note here in the context of the talk, but that's sometimes you have biological experiments that give you drivers of disease, for example from knockouts or knockdowns, and so on.",
                    "label": 0
                },
                {
                    "sent": "And then the question is, can actually target something in that environment that changes the disease phenotype back to healthy and quite often that's not the case.",
                    "label": 0
                },
                {
                    "sent": "So this figure comes from that paper as well.",
                    "label": 0
                },
                {
                    "sent": "So what they looked at is the number of cancer drug targets.",
                    "label": 1
                },
                {
                    "sent": "So 150, four counts and rocks.",
                    "label": 0
                },
                {
                    "sent": "Out of which 85 are targeted agents, someone specific so you cytotoxic agents for example, and there are 553 cancer gene products that drive disease and only 30 or so actually overlap between both spaces.",
                    "label": 1
                },
                {
                    "sent": "In this quite often means that if you have a loss of function mutation for example, you can of course not target the gene in order to gain function again.",
                    "label": 0
                },
                {
                    "sent": "Yeah, so genetic experiments to find phenotypes or something quite different from small molecule modulators.",
                    "label": 1
                },
                {
                    "sent": "So it's quite a different question.",
                    "label": 0
                },
                {
                    "sent": "So it can target something in the network neighborhood maybe.",
                    "label": 0
                }
            ]
        },
        "clip_6": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "And so this is about current drug targets.",
                    "label": 0
                },
                {
                    "sent": "So the point is, an current chemical space that targets proteins isn't quite a narrow area of protein space in chemical space.",
                    "label": 0
                },
                {
                    "sent": "That's the key message here.",
                    "label": 0
                },
                {
                    "sent": "And then there was another study by Tutor Oprea, and so he looked up what is actually the again the protein space that is targeted by current drugs.",
                    "label": 0
                },
                {
                    "sent": "But he also asked the question what are additional proteins where we either have ligands or we know something about biological function.",
                    "label": 0
                },
                {
                    "sent": "So what are the easy next areas to step into if you wish?",
                    "label": 0
                },
                {
                    "sent": "So he classified protein targets into 4 four categories.",
                    "label": 0
                },
                {
                    "sent": "One was teklin, so that's clinical proteins.",
                    "label": 1
                },
                {
                    "sent": "So these are the ones that are linked to current drug activity of drugs on the market.",
                    "label": 1
                },
                {
                    "sent": "The next one is tkam, so these are proteins where we know ligands at different activity cut offs because there's different activity classes, so we have different infinities of binding and so on, and so these are proteins where we have legions but which are don't have a clinical compound, for example, and then the third category is T bio.",
                    "label": 1
                },
                {
                    "sent": "So these are proteins which have a confirmed link to a disease but not necessarily ligand and the 4th category.",
                    "label": 0
                },
                {
                    "sent": "These are the proteins or genes and proteins.",
                    "label": 0
                },
                {
                    "sent": "But we don't know much about their function, and the idea was to investigate which fraction of all protein space is actually currently targeted.",
                    "label": 0
                },
                {
                    "sent": "Where do we have ligands?",
                    "label": 0
                },
                {
                    "sent": "Where do we know something about biological function and were don't we have any clue?",
                    "label": 0
                },
                {
                    "sent": "M and the key message.",
                    "label": 0
                }
            ]
        },
        "clip_7": {
            "is_summarization_sample": false,
            "summarization_data": [
                {
                    "sent": "So that paper is probably this figure here.",
                    "label": 0
                },
                {
                    "sent": "So what you see here is here in the inner circle is 4 different categories, so these are the clinical drugs.",
                    "label": 0
                },
                {
                    "sent": "A clinical proteins.",
                    "label": 0
                },
                {
                    "sent": "These are the proteins which have a chemical ligand, the ones that are linked to biological function and the ones where we don't know anything.",
                    "label": 0
                },
                {
                    "sent": "And the point is that the drugs we have currently on the market, they only target about 3% or so of the proteome that we know right now, and so that's that's a tiny fraction.",
                    "label": 0
                },
                {
                    "sent": "And the proteins where we have ligands, Ohio.",
                    "label": 0
                },
                {
                    "sent": "Compounds and this at least twice as much as it currently targeted.",
                    "label": 0
                },
                {
                    "sent": "Proteome of all drugs.",
                    "label": 0
                },
                {
                    "sent": "OK, so here we know ligands and for about half or so for proteins and we have some function or disease links.",
                    "label": 0
                },
                {
                    "sent": "OK, so the point here is current drug discovery.",
                    "label": 0
                },
                {
                    "sent": "Again, it's focused on a tiny fraction of protein space in many other cases we have ligands.",
                    "label": 0
                },
                {
                    "sent": "Or we know something about biological function.",
                    "label": 0
                },
                {
                    "sent": "So it would be beneficial to focus some of the efforts on those further protein spaces where we have some information already.",
                    "label": 0
                },
                {
                    "sent": "It might be easier to discover new.",
                    "label": 0
                }
            ]
        },
        "clip_8": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "Box.",
                    "label": 0
                },
                {
                    "sent": "An and one of those.",
                    "label": 0
                },
                {
                    "sent": "That's a different way to plot related information, so these are proteins with disease associations.",
                    "label": 1
                },
                {
                    "sent": "Anamim says 3000 proteins also, and these are the protein classes, and you see that in some areas GPC ours or nuclear hormone receptors.",
                    "label": 0
                },
                {
                    "sent": "For example, we have quite a large fraction of that protein class that is exploited by current drugs, but in some other classes, so by definition, for example, often GPC ours, we know something about the biological function, but we don't know anything about ligands, but also in other classes.",
                    "label": 0
                },
                {
                    "sent": "And quite often we know something about biological functions.",
                    "label": 0
                },
                {
                    "sent": "Or we have chemical ligands but we don't have drugs on the market.",
                    "label": 0
                },
                {
                    "sent": "OK, that is overall only the minority of all proteins, so again, there's quite a lot of focus on what has been established before already.",
                    "label": 0
                },
                {
                    "sent": "So why do I talk about this?",
                    "label": 0
                },
                {
                    "sent": "The point is, quite often if you design something novel, it needs to be based on what you know and what you know is quite bias and limited when it comes to chemical space that is used right now as well as protein space that is targeted.",
                    "label": 0
                },
                {
                    "sent": "So someone comes with a completely new target class for example, and you have to design chemistry.",
                    "label": 0
                },
                {
                    "sent": "That's a completely novel question.",
                    "label": 0
                },
                {
                    "sent": "You cannot necessarily transfer to that new question, which has implications for library design for screening, for example.",
                    "label": 0
                }
            ]
        },
        "clip_9": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "And an interesting part from the paper was also this one here, so that the rich get richer basically.",
                    "label": 1
                },
                {
                    "sent": "So what you see here is the dark genome at the one with annotated biological function as well as chemical ligands and the blue one.",
                    "label": 0
                },
                {
                    "sent": "That's the taek Lim.",
                    "label": 0
                },
                {
                    "sent": "So that's the targets.",
                    "label": 0
                },
                {
                    "sent": "The proteins that are linked to clinical drugs, and what you see is that of course, in literature.",
                    "label": 0
                },
                {
                    "sent": "You see, there's most known about the protein targets with clinical compounds.",
                    "label": 0
                },
                {
                    "sent": "That's the way we would expect it.",
                    "label": 0
                },
                {
                    "sent": "But also, for example, when you look at grants.",
                    "label": 0
                },
                {
                    "sent": "So current research, basically most of that research is done on those targets as well.",
                    "label": 0
                },
                {
                    "sent": "So it's basically where you have lots of information already.",
                    "label": 0
                },
                {
                    "sent": "There's more literature, so if you write a grant application, you have more success rate because there's a good reason to work in that area.",
                    "label": 0
                },
                {
                    "sent": "But that's the problem, right?",
                    "label": 0
                },
                {
                    "sent": "You cannot discover much that is new, and so there's a.",
                    "label": 0
                },
                {
                    "sent": "There's a certain trend to also stay in the areas that are known already.",
                    "label": 0
                },
                {
                    "sent": "OK, so.",
                    "label": 0
                }
            ]
        },
        "clip_10": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "To summarize that part, So what is the current rocked and druggable protein space?",
                    "label": 1
                },
                {
                    "sent": "So drug discovery quite often tends to follow past successes, and that's true for protein space as well as chemical space.",
                    "label": 1
                },
                {
                    "sent": "So current drugs are focused on quite a small number of proteins, but I think there's some information in those databases and there was actually a big U project.",
                    "label": 0
                },
                {
                    "sent": "It's in the forest portal at the NIH that your work done.",
                    "label": 0
                },
                {
                    "sent": "So all that information can be accessed online.",
                    "label": 1
                },
                {
                    "sent": "In many cases, disease connection in small molecule ligands are known, so it should be quite easy based on currently existing information.",
                    "label": 0
                },
                {
                    "sent": "To match the two better, so to move and to exploit this T bio antique M space.",
                    "label": 0
                },
                {
                    "sent": "So sometimes the question right now is do we need novel chemistry or new modalities to target new targets?",
                    "label": 0
                },
                {
                    "sent": "Well, that's difficult to say because of the completely new question.",
                    "label": 0
                },
                {
                    "sent": "It might be likely, and there are quite a lot of fused by politics, for example and so on.",
                    "label": 0
                },
                {
                    "sent": "Micro cycles that are coming up.",
                    "label": 0
                },
                {
                    "sent": "But even the current proteome where we have ligands and that is unknown.",
                    "label": 1
                }
            ]
        },
        "clip_11": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "Not as well.",
                    "label": 0
                },
                {
                    "sent": "And yesterday there was a comment that we want to have selective ligands in order to decrease the number of side effects and also went through that paper again yesterday and there was a presentation actually of Cura yesterday, so he was looking into the question of whether that's really true.",
                    "label": 0
                },
                {
                    "sent": "If you have a selective ligand, are you more likely to see fewer side effects?",
                    "label": 1
                },
                {
                    "sent": "So is promiscuity correlated to the number of side effects?",
                    "label": 1
                },
                {
                    "sent": "And that's actually not really the case.",
                    "label": 0
                },
                {
                    "sent": "So what you have here is the number of targets annotated per drug from one 200 or so.",
                    "label": 0
                },
                {
                    "sent": "And the number of adverse events per drug, so it's on a log scale in two year few targets, bedrock here 100 and you might see a trend, but of course it's difficult to estimate the density here.",
                    "label": 0
                },
                {
                    "sent": "I don't know if the underlying data cannot, so cannot really say, but what you see is that in many cases even word ruckus only with single target you can see a huge number of side effects as well, so that's a it's a difficult question to answer, but if you have a more selective compound, are less likely to see side effects in the end because of course you have on target related side effects as well.",
                    "label": 0
                },
                {
                    "sent": "So it's difficult to say.",
                    "label": 0
                },
                {
                    "sent": "Some people argue if you modulate in network and multiple notes, you're actually less likely to see side effects.",
                    "label": 0
                },
                {
                    "sent": "Depends on the case.",
                    "label": 0
                }
            ]
        },
        "clip_12": {
            "is_summarization_sample": false,
            "summarization_data": [
                {
                    "sent": "So this was the protein part biological part.",
                    "label": 0
                },
                {
                    "sent": "So the point is quite a lot of bioactivity in large we have right now is focused on few proteins, is quite biased and repetitive.",
                    "label": 0
                },
                {
                    "sent": "And then there's a question of course.",
                    "label": 0
                },
                {
                    "sent": "Do we also need to look into other drug properties that are relevant?",
                    "label": 0
                },
                {
                    "sent": "And there was this Lipinski paper, some of you might be aware of.",
                    "label": 0
                },
                {
                    "sent": "It's now 20 years or 22 years old, so he said he came up with those drug like properties.",
                    "label": 0
                },
                {
                    "sent": "It's a concept or term that has been used in the wrong context sometimes, so that's only referring to.",
                    "label": 0
                },
                {
                    "sent": "Orally absorbed crux.",
                    "label": 0
                },
                {
                    "sent": "So companies will take orally is only true for 90% of the cases and not for those cases we have active transport.",
                    "label": 0
                },
                {
                    "sent": "So vitamins for example steroids, they regularly violate the rule of five, but they are still actively transported for example, and so there's no problem with that.",
                    "label": 0
                },
                {
                    "sent": "But in any case that was the rule, so you have particular physical chemical properties that might be relevant for library designer picking compounds, so such as lipophilicity, it tells you whether compound goes through a membrane.",
                    "label": 0
                },
                {
                    "sent": "So that's important.",
                    "label": 0
                },
                {
                    "sent": "Of course, if you have a phenotypic screen as well.",
                    "label": 0
                },
                {
                    "sent": "So if you have good balance between solubility and permeability, molecular weight and hydrogen bond donors and accept US and OK.",
                    "label": 0
                },
                {
                    "sent": "But that was the Lipinski rules and there was this recent follow up paper which actually checked does what Lipinski says is that supported by data and so historically this Lipinski rule did apply so many of the FDA approved or rocks they were fulfilling the Lipinski rules that are listed above here as well.",
                    "label": 0
                }
            ]
        },
        "clip_13": {
            "is_summarization_sample": false,
            "summarization_data": [
                {
                    "sent": "Actually the whole the whole day to the properties of drugs that were approved, they changed my laundry here.",
                    "label": 0
                },
                {
                    "sent": "So here you see the distribution of properties only molecular weight historically up to 97.",
                    "label": 0
                },
                {
                    "sent": "It's up to the Lipinski paper and you see that 90% of drugs were actually below molecular weight of 500.",
                    "label": 0
                },
                {
                    "sent": "So that's the blue part.",
                    "label": 0
                },
                {
                    "sent": "But if you go into the last 20 years, you see that you have quite a large number of compounds that are above this particular cut off.",
                    "label": 0
                },
                {
                    "sent": "OK, so basically it can be very dangerous to take historical data, make a rule of that, and think that's generally valid concept.",
                    "label": 0
                },
                {
                    "sent": "It's only biased by what people have done so far, and so apparently there's quite a this different chemical space you can use as well in screens and later on drugs.",
                    "label": 0
                },
                {
                    "sent": "Which can be kind of working there.",
                    "label": 0
                }
            ]
        },
        "clip_14": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "Clinic and there's even an anti correlation.",
                    "label": 0
                },
                {
                    "sent": "I found that quite interesting to see, so that's the number of new chemical entities.",
                    "label": 1
                },
                {
                    "sent": "So new drugs on the market basically over the last 100 years or so or 70 years and you see that in the last 10 years there was quite an increase of the number of drugs approved, but if you correlate that to the.",
                    "label": 0
                }
            ]
        },
        "clip_15": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "Molecular weight ranges and so this one here is below 500.",
                    "label": 1
                },
                {
                    "sent": "The red part is above 500.",
                    "label": 0
                },
                {
                    "sent": "You see that there actually anticorrelated, so you have more drug approvals, but at the same time drugs gets heavier.",
                    "label": 0
                },
                {
                    "sent": "OK, so it's dangerous to use concepts such as Lipinski concept to design libraries.",
                    "label": 0
                },
                {
                    "sent": "You have to be very careful.",
                    "label": 0
                }
            ]
        },
        "clip_16": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "But of course they are solubility or her requirements, and that's if you have bioactivity data.",
                    "label": 0
                },
                {
                    "sent": "What people routinely don't do, and also we have that property and Campbell or in public databases quite alot, don't check the solubility of a compound.",
                    "label": 0
                },
                {
                    "sent": "So get a bioactivity.",
                    "label": 0
                },
                {
                    "sent": "You didn't shake solubility, so your data is wrong basically.",
                    "label": 0
                },
                {
                    "sent": "So what's the point here?",
                    "label": 0
                },
                {
                    "sent": "First part?",
                    "label": 0
                },
                {
                    "sent": "So the currently drugged proteome and requirements for chemistry, so there's a huge bias of research efforts in a minority of proteins between oh ligands form anymore and targets of interest and chemical space considered to be relevant, they change.",
                    "label": 1
                },
                {
                    "sent": "So concept of which chemical space to actually need to design my library.",
                    "label": 0
                },
                {
                    "sent": "That's a tricky concept because the knowledge that we have that is changing overtime the proteins that we need to target so we can use that data, but it certainly doesn't predict everything for future targets that we want to modulate as well.",
                    "label": 0
                },
                {
                    "sent": "So and then there are two parts to a virtual screening as well as libraries on.",
                    "label": 0
                },
                {
                    "sent": "So what does virtual screening refer to?",
                    "label": 0
                },
                {
                    "sent": "So that's the starting point.",
                    "label": 0
                },
                {
                    "sent": "In case negative molecule is known and there are two parts in here is how can I describe molecules and how can I calculate similarities between molecules?",
                    "label": 0
                },
                {
                    "sent": "It seems like a trivial concept and in some sense the idea is trivial, but similarity is one of those birds that humans use.",
                    "label": 0
                },
                {
                    "sent": "That means everything and nothing because it depends on how you perceive similarity.",
                    "label": 0
                },
                {
                    "sent": "How do you put it in?",
                    "label": 0
                }
            ]
        },
        "clip_17": {
            "is_summarization_sample": false,
            "summarization_data": [
                {
                    "sent": "So descriptor space.",
                    "label": 0
                }
            ]
        },
        "clip_18": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "So let's see what we can do here.",
                    "label": 0
                },
                {
                    "sent": "So virtual screening and similarity searching.",
                    "label": 1
                },
                {
                    "sent": "So if you compare two molecules, ligand based similarity searching is basically the same as virtual screening, and it's quite often employed when no target structure is known.",
                    "label": 1
                },
                {
                    "sent": "Of course you can do docking, but scoring functions are not really good enough in many cases.",
                    "label": 0
                },
                {
                    "sent": "So many cases you can do a similarity search to come up with GNU Bio active.",
                    "label": 0
                }
            ]
        },
        "clip_19": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "Chemical matter, and that's based on one core assumption, and that's the assumption of all computer aided drug discovery basically, and that is the assumption that similar molecules have similar properties, and that seems like a trivial statement as well.",
                    "label": 1
                },
                {
                    "sent": "When I was doing my postdoc at Novartis, we sometimes joke that we need to write a follow up paper to this molecular similarity principle, and there's the molecular weight principle, so larger molecules are heavier.",
                    "label": 0
                },
                {
                    "sent": "We didn't publish that yet, but the question is, how do we actually describe similarity of molecules?",
                    "label": 0
                },
                {
                    "sent": "Humans are very good at perceiving similarity.",
                    "label": 1
                },
                {
                    "sent": "But the question is, how do you make that explicit to computer?",
                    "label": 0
                },
                {
                    "sent": "Sometimes you can learn it from the data, but often you don't have enough data and then you need to make an explicit definition of descriptors.",
                    "label": 0
                },
                {
                    "sent": "For example and you need 2 steps for that.",
                    "label": 0
                },
                {
                    "sent": "So the first one is molecular representation and the second one is a similarity or distance measure of two molecules.",
                    "label": 0
                }
            ]
        },
        "clip_20": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "M and virtual screening in some sense is kind of a schizophrenic exercise because what we hope is that the property of interest remains.",
                    "label": 1
                },
                {
                    "sent": "So if one active molecule research database I found another active molecule, but other properties change, so we want to go to different chemical space that is better soluble, less metabolically labile, and so on.",
                    "label": 0
                },
                {
                    "sent": "And what do you assume?",
                    "label": 0
                },
                {
                    "sent": "And that's very important.",
                    "label": 1
                },
                {
                    "sent": "Here is a somewhat smooth activity landscape, so here's for example.",
                    "label": 0
                },
                {
                    "sent": "Here are descriptor axis.",
                    "label": 0
                },
                {
                    "sent": "So this is meant to be a plot of chemical space.",
                    "label": 0
                },
                {
                    "sent": "And if by activity of a random by activity here on the other axis, and you see that if peaks here sober by activity changes quite abruptly.",
                    "label": 0
                },
                {
                    "sent": "But you have other areas, I think here with the landscape is much more smooth.",
                    "label": 0
                },
                {
                    "sent": "But the problem here is chemical space is not 2 dimensional or three dimensional, it's whatever 100 dimensional.",
                    "label": 0
                },
                {
                    "sent": "So so in that causes problems for diversity selection as well As for plots like that.",
                    "label": 0
                },
                {
                    "sent": "So never believe a plot where plot molecular structures in 2D for similarity.",
                    "label": 0
                },
                {
                    "sent": "If you look at neighboring molecules they virtually never.",
                    "label": 0
                },
                {
                    "sent": "Look similar, but this is the assumption here, so we need to have some smoothness in the activity landscape so similar molecules have some kind of similar.",
                    "label": 0
                }
            ]
        },
        "clip_21": {
            "is_summarization_sample": false,
            "summarization_data": [
                {
                    "sent": "Properties then you.",
                    "label": 0
                },
                {
                    "sent": "So if you have a query structure you're representing molecules in a descriptor space quite often in a binary bit string, and then.",
                    "label": 0
                },
                {
                    "sent": "So this is the first question, how do you get here?",
                    "label": 0
                },
                {
                    "sent": "And then you compare the molecule to others.",
                    "label": 0
                },
                {
                    "sent": "So in this case those three molecules have a similar property to this one, they inhibit anger tensin converting enzyme, but they're not obviously structurally similar.",
                    "label": 0
                },
                {
                    "sent": "So the question is so versus similarity in here.",
                    "label": 0
                },
                {
                    "sent": "And if you have a chemist or look at patterns here you see if they might bonds for example in those molecules.",
                    "label": 0
                },
                {
                    "sent": "So there are some underlying patterns that are similar, but we need to have a proper representation too.",
                    "label": 0
                }
            ]
        },
        "clip_22": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "Exploit that in practice.",
                    "label": 0
                },
                {
                    "sent": "So what does it look like in practice?",
                    "label": 0
                },
                {
                    "sent": "Similarity searching so you have one compound you use it to rank.",
                    "label": 1
                },
                {
                    "sent": "Usually a whole database, so it can be virtual molecules as well there.",
                    "label": 0
                },
                {
                    "sent": "Now companies like Enamine for example awaken by 100 million or so molecules for $10.",
                    "label": 0
                },
                {
                    "sent": "Sorry, $400 or so piece so you can scan that quite quickly, efficiently, computationally.",
                    "label": 0
                },
                {
                    "sent": "What do you assume is that if your query is active against your enzyme or receptor your target, then the assumption is that the most similar compounds are also active against that protein.",
                    "label": 1
                },
                {
                    "sent": "Assuming that representation and similarity measure works.",
                    "label": 0
                }
            ]
        },
        "clip_23": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "So what you want to go from is so this is the list of our molecules in your database.",
                    "label": 0
                },
                {
                    "sent": "The red lines are the active compounds.",
                    "label": 0
                },
                {
                    "sent": "Usually they are randomly distributed, but if you sort them according to similarity to a query which is active, you have an enrichment of molecules at the top.",
                    "label": 1
                },
                {
                    "sent": "Yeah.",
                    "label": 0
                }
            ]
        },
        "clip_24": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "Among the most similar molecules, and then, as I think know you mentioned yesterday already, you can see among the, let's say, 10% of the most similar molecules, 60% of active source are found, and then you can calculate an enrichment if you wanted to get there earlier as well.",
                    "label": 1
                },
                {
                    "sent": "But the question is what does that number really tell me?",
                    "label": 0
                },
                {
                    "sent": "It tells me something.",
                    "label": 0
                },
                {
                    "sent": "It tells me how many of those molecules are active, but that's not the only thing I want because.",
                    "label": 0
                }
            ]
        },
        "clip_25": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "Of course, what I want is also some novelty.",
                    "label": 0
                },
                {
                    "sent": "I don't always want to find the same molecule, so you also need to see to have some kind of novelty measure and quite often, but it can count as how many different schedules do you find, but for practical purposes you would ideally like to do parallel prospective validation, so you have five different methods.",
                    "label": 1
                },
                {
                    "sent": "You test 10,000 compounds and you see what are your hit rates.",
                    "label": 1
                },
                {
                    "sent": "Ideally you would like to do that, but practically you need to do it on historical data and that's the problem.",
                    "label": 0
                },
                {
                    "sent": "Again, with those biases you have quite a lot of analogs in your databases.",
                    "label": 0
                },
                {
                    "sent": "So you need to do clustering.",
                    "label": 0
                },
                {
                    "sent": "For example is no illustrated.",
                    "label": 0
                },
                {
                    "sent": "You need to cluster your compounds.",
                    "label": 0
                },
                {
                    "sent": "That is one option.",
                    "label": 0
                },
                {
                    "sent": "You can also do time split validation so and that's some companies like that because that's in their view most predicted for novel project.",
                    "label": 0
                },
                {
                    "sent": "So can I predict for the next project.",
                    "label": 0
                },
                {
                    "sent": "In my opinion time is not the variable to consider the clustering, I prefer because the question is whole novel is my chemistry is but at times with validation is another option to do as well.",
                    "label": 0
                }
            ]
        },
        "clip_26": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "Then there's one big difficulty with validations, and that's always the question.",
                    "label": 1
                },
                {
                    "sent": "Does your model actually learn the property of interest?",
                    "label": 1
                },
                {
                    "sent": "And sometimes that's not the case, because you can get spurious correlations, and so for example, if you're modeling activity in a cellular essay.",
                    "label": 0
                },
                {
                    "sent": "So let's say so from a high content screen.",
                    "label": 0
                },
                {
                    "sent": "Do you actually model activity against the pathway?",
                    "label": 0
                },
                {
                    "sent": "Or you do have a kind of confounding factors such as permeability?",
                    "label": 0
                },
                {
                    "sent": "So do you model actually permeability of your company as a confounding factor?",
                    "label": 0
                },
                {
                    "sent": "Or if you're small compound sets, so let's for example one.",
                    "label": 0
                },
                {
                    "sent": "Project we worked on recently.",
                    "label": 0
                },
                {
                    "sent": "So can you classify compounds that are cause drug induced liver injury?",
                    "label": 0
                },
                {
                    "sent": "We have only a few hundred data points and then the question is if you have two classes.",
                    "label": 1
                },
                {
                    "sent": "I actually modeling delete so active and inactive, toxic and non toxic or do you model a different distribution?",
                    "label": 0
                },
                {
                    "sent": "Let's say of ATC codes if you have different types of compounds with different bioactivity classes in one side versus the other, maybe that's what your model and that can easily be the case if you model by activities that you actually model, you're a correlated.",
                    "label": 0
                },
                {
                    "sent": "Variables with your.",
                    "label": 0
                }
            ]
        },
        "clip_27": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "Property of interest that happens very often.",
                    "label": 0
                },
                {
                    "sent": "OK, so in the first step you need to describe your molecules in some way and there's no natural way to describe chemistry because always there different aspects of chemical structure that matter and there only three examples here.",
                    "label": 1
                },
                {
                    "sent": "So sometimes if you model toxicity, for example is reactivity that met us, so the particular functional group.",
                    "label": 0
                },
                {
                    "sent": "Can.",
                    "label": 0
                },
                {
                    "sent": "My Groupon ago particular chemical reaction.",
                    "label": 1
                },
                {
                    "sent": "Sometimes it's the surface, for example, for ligand protein directions, sometimes is the physical chemical property for permeability of solubility, and that is something.",
                    "label": 0
                },
                {
                    "sent": "You would probably like to make explicit to the model before hand that some argument that we can learn from the data, probably with an ideal infinitely large, dare say you probably could, but quite often in practice we don't have that and there's no start, not end of the molecule.",
                    "label": 0
                },
                {
                    "sent": "So the question is, how do we actually encode 3D information?",
                    "label": 0
                },
                {
                    "sent": "We have confirmation of flexibility, different protein.",
                    "label": 0
                }
            ]
        },
        "clip_28": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "States and so on.",
                    "label": 0
                },
                {
                    "sent": "So this is a slight I was always including to illustrate how do we actually make explicit to the computer to recognize objects?",
                    "label": 1
                },
                {
                    "sent": "And there's now in the last five years or so there was of course quite a progress when it comes to convolutional networks and so on.",
                    "label": 0
                },
                {
                    "sent": "So part of that you can probably learn from the images about humans actually have very good at generalizing from images, so these are all Tracy obviously, but they have quite different shapes in different colors.",
                    "label": 0
                },
                {
                    "sent": "And some of them don't even have leaf sensor on, so they're quite away quite far away from your examples from the training set if you wish so many cases, I believe, especially in their life Sciences, what we need is combination, such as we've seen the Macau Macau algorithm as well a combination of some type of tight information or prior knowledge.",
                    "label": 0
                },
                {
                    "sent": "Whatever you want to call that, as well as data from the models.",
                    "label": 0
                },
                {
                    "sent": "So, for example, if you learn here, the tree consists of the trunk, and if you recognize the trunk that's in part of the tree, you can have some kind of structured model.",
                    "label": 0
                },
                {
                    "sent": "And probably that would help in areas, especially where we don't have enough data, so humans are good at recognizing patterns, but computers are some.",
                    "label": 0
                }
            ]
        },
        "clip_29": {
            "is_summarization_sample": false,
            "summarization_data": [
                {
                    "sent": "Times and not that good either.",
                    "label": 0
                },
                {
                    "sent": "So how can we classify how can we describe molecules to the computer?",
                    "label": 0
                },
                {
                    "sent": "So this is kind of a standard way to classify descriptors so we can have different dimensionalities of of molecules of descriptors.",
                    "label": 0
                },
                {
                    "sent": "So some of molecular weight, some are fragments.",
                    "label": 0
                },
                {
                    "sent": "Then we have three descriptors.",
                    "label": 0
                },
                {
                    "sent": "We could include confirmations.",
                    "label": 0
                },
                {
                    "sent": "You can also do and that was at least two or three papers.",
                    "label": 0
                },
                {
                    "sent": "Right now you can separate represent the molecule as a 2D drawing represented in different orientations if you wish, put that into a network and then actually those representations.",
                    "label": 0
                },
                {
                    "sent": "Surprisingly to me as well perform about on par with Morgan finger circular fingerprints and so that is quite surprising to me because Morgan fingerprints were quite for quite a long time 10 or 15 years.",
                    "label": 0
                },
                {
                    "sent": "The benchmark be CFP fingerprints for example.",
                    "label": 0
                },
                {
                    "sent": "They're still quick to calculate.",
                    "label": 0
                },
                {
                    "sent": "There are many advantages in practice, but still from images you actually get quite a lot of information as well.",
                    "label": 0
                },
                {
                    "sent": "There was this toxic colors, I think.",
                    "label": 0
                },
                {
                    "sent": "Paper and we.",
                    "label": 0
                }
            ]
        },
        "clip_30": {
            "is_summarization_sample": false,
            "summarization_data": [
                {
                    "sent": "Publishing is about recently.",
                    "label": 0
                },
                {
                    "sent": "So why should we actually use what sounds very simple descriptors?",
                    "label": 0
                },
                {
                    "sent": "1 dimensional descriptors and they tell us quite a lot about particular relevant properties of molecules.",
                    "label": 0
                },
                {
                    "sent": "Even if you have a simple descriptors such as lock P. So that tells you how lipophilic is, your compound doesn't stay in water or lipophilic environment.",
                    "label": 0
                },
                {
                    "sent": "That tells us quite a lot about whether common gets through membranes.",
                    "label": 0
                },
                {
                    "sent": "For example, for practical purposes, that's hugely relevant.",
                    "label": 0
                },
                {
                    "sent": "So basically, if you build a bioactivity model and you have a deep learning model or random forests or so always.",
                    "label": 0
                },
                {
                    "sent": "Do some reality check.",
                    "label": 0
                },
                {
                    "sent": "How does my baseline model behave so you can scramble your model, but it can also say how good is my model if I just use log P as a single descriptor or very limited set of descriptors, simply to see if there's some very simple trivial correlation in your data set that you can pick up.",
                    "label": 0
                }
            ]
        },
        "clip_31": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "You can use 2D descriptors as well, and quite often they're fragment based or fingerprints.",
                    "label": 1
                },
                {
                    "sent": "For example.",
                    "label": 0
                },
                {
                    "sent": "They work very well, they are quick to calculate, so you can calculate circular fingerprints for about 10,000 molecules a second or so.",
                    "label": 1
                }
            ]
        },
        "clip_32": {
            "is_summarization_sample": false,
            "summarization_data": [
                {
                    "sent": "It's probably even more.",
                    "label": 0
                },
                {
                    "sent": "Yeah, disrupt him yesterday already so you look at every heavy Atom in the next layout, the next layer, and so that seems to be the right level of abstraction.",
                    "label": 0
                }
            ]
        },
        "clip_33": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "The molecule is interesting that some molecular descriptors actually reused for purpose.",
                    "label": 0
                },
                {
                    "sent": "They were not intended to be used for, and they perform remarkably well, and one of those examples is MDL keys, which you might have come across already, so they were actually invented in the 80s or so in order to speed up searches, I mean, their computational power was huge problem.",
                    "label": 1
                },
                {
                    "sent": "So the question was, how can I find all molecules that have particular functional groups?",
                    "label": 0
                },
                {
                    "sent": "So that's a it's a key set, so it's a bit string, basically of 166 bits.",
                    "label": 0
                },
                {
                    "sent": "So it's relatively limited.",
                    "label": 0
                },
                {
                    "sent": "There's a longer one as well, and there's very simple definitions.",
                    "label": 0
                },
                {
                    "sent": "So does my molecule contain a heteroatom?",
                    "label": 0
                },
                {
                    "sent": "Doesn't have a carbon and CC double bond, and so on.",
                    "label": 0
                },
                {
                    "sent": "And this is actually it was used for cataloging chemical information.",
                    "label": 0
                },
                {
                    "sent": "More recently, people have used it for classification and so on as well, and there seems to work remarkably well or they they are very coarse grained as so many areas that program not sufficient.",
                    "label": 0
                },
                {
                    "sent": "But in some areas you can use very descriptors that have been used for every section or descriptive features.",
                    "label": 1
                },
                {
                    "sent": "Key sets that were used for one particular purpose, and you can use them even for similarity searching and so on.",
                    "label": 0
                },
                {
                    "sent": "In many cases you get good results with that, although you shouldn't in theory.",
                    "label": 0
                }
            ]
        },
        "clip_34": {
            "is_summarization_sample": false,
            "summarization_data": [
                {
                    "sent": "And three dimensional descriptors in theory, should perform better because you are looking at hysterical spatial information of features in the molecule.",
                    "label": 0
                },
                {
                    "sent": "But in practice, in my experience that's quite often does not lead to superior results because you have conformational flexibility, so you increase computational cost.",
                    "label": 0
                },
                {
                    "sent": "I don't know 100 fold or even 1000 fold in some cases, but that doesn't give you much more information.",
                    "label": 0
                },
                {
                    "sent": "So in my experience, that is in many cases.",
                    "label": 0
                }
            ]
        },
        "clip_35": {
            "is_summarization_sample": false,
            "summarization_data": [
                {
                    "sent": "Not a good trade off, but what you can do is you can use pharmacophore IK descriptors for example so they are quick to calculate.",
                    "label": 0
                },
                {
                    "sent": "So you simply calculate properties and distances of atoms in a molecule and you put that into a bit string.",
                    "label": 0
                },
                {
                    "sent": "So that gives you a short representation.",
                    "label": 0
                },
                {
                    "sent": "Avail away again, which you can use for similarity searching.",
                    "label": 0
                },
                {
                    "sent": "So in practice that can be a very diverse, very popular 15 years ago or so.",
                    "label": 0
                },
                {
                    "sent": "In order to search large chemical databases, and in order to a particular go to novel scaffolds as well, because that's what you want, right?",
                    "label": 0
                },
                {
                    "sent": "So you want to have a similar.",
                    "label": 0
                },
                {
                    "sent": "Arrangement of features that give you activity but different underlying kemmis.",
                    "label": 0
                }
            ]
        },
        "clip_36": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "So why can conformational space actually be tricky?",
                    "label": 1
                },
                {
                    "sent": "So that's a short molecular dynamics.",
                    "label": 0
                },
                {
                    "sent": "Simulation of this anger tends in converting enzyme inhibitor, and there are some distances distance distributions market here.",
                    "label": 1
                },
                {
                    "sent": "So the distance of that carbon to this carboxylic acid for example.",
                    "label": 1
                },
                {
                    "sent": "And if you observe that molecule in solution and it wiggles around what you see is that this distance can be anywhere between 18 angstroms and seven angstroms or so.",
                    "label": 0
                },
                {
                    "sent": "OK, so many molecules are hugely flexible and this illustrates one of the problems by using 3D information can be really tricky.",
                    "label": 0
                },
                {
                    "sent": "If you include molecules for the computer.",
                    "label": 0
                }
            ]
        },
        "clip_37": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "Descriptors all behave differently, and that can be quite a problem.",
                    "label": 0
                },
                {
                    "sent": "So you have two molecules.",
                    "label": 0
                },
                {
                    "sent": "I guess it's a.",
                    "label": 0
                },
                {
                    "sent": "Do you have two molecules, so this particular query structure and this target structure and the question is, are those two molecules similar and even if you're not a clemency will probably say OK, they look quite different quite apparently, but if you use different types of descriptors, for example type Tatum, triangles, type graph triangles and so on, they actually rank those molecules.",
                    "label": 0
                },
                {
                    "sent": "The similarity of those molecules.",
                    "label": 1
                },
                {
                    "sent": "At position 7 or 23 out of 1000 pounds, they are compared to and so that means that those descriptors perceive those molecules as pretty similar.",
                    "label": 0
                },
                {
                    "sent": "OK, and that's not what agrees with intuition.",
                    "label": 0
                },
                {
                    "sent": "OK, so not every molecular similarity or distance measure would agree with what you would expect to him.",
                    "label": 0
                },
                {
                    "sent": "On the other hand, if you look into shape based descriptors, for example as you would expect, the shape of those two entities is entirely distinct, so they are here.",
                    "label": 0
                },
                {
                    "sent": "The similarities ranked very low.",
                    "label": 0
                },
                {
                    "sent": "And let's say in case you lose molecular descriptors and you are concerned about the behavior and that's one of the papers you might want to look up.",
                    "label": 1
                },
                {
                    "sent": "So that gives some illustrations.",
                    "label": 0
                },
                {
                    "sent": "Also, if you have a CFP for fingerprints, for example, what they don't consider as was alluded to in the morning hysteric chemistry.",
                    "label": 0
                },
                {
                    "sent": "But another thing is repeat units, for example.",
                    "label": 0
                },
                {
                    "sent": "So you have features.",
                    "label": 0
                },
                {
                    "sent": "If they are there once or 20 times, the descriptor doesn't care, which means you can have a much larger molecule that sets the same features, and those molecules are then perceived as similar.",
                    "label": 0
                },
                {
                    "sent": "Although they aren't, if you have much larger molecule, doesn't fit into the binding sites, quite a different molecule.",
                    "label": 0
                },
                {
                    "sent": "So EC FP fingerprints have this sensitivity as well as terpenes for example, so other types of repeat units in natural products that they don't pick that up as well.",
                    "label": 0
                },
                {
                    "sent": "So every descriptor some kind of weaknesses.",
                    "label": 0
                }
            ]
        },
        "clip_38": {
            "is_summarization_sample": false,
            "summarization_data": [
                {
                    "sent": "Yeah, so representation is one step, then the comparison of the molecules is the next one here.",
                    "label": 0
                },
                {
                    "sent": "Would like to point out simply, there are three different ways to measure similarity or dissimilarity, and I would like to point out the difference between similarity distance and dissimilarity because the.",
                    "label": 0
                }
            ]
        },
        "clip_39": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "It is not as trivial as it might sound.",
                    "label": 0
                },
                {
                    "sent": "So if you compare molecules, usually body uses similarity coefficients and there's one coefficient that is used quite a lot.",
                    "label": 1
                },
                {
                    "sent": "That's attorney model coefficient, so you simply calculating how many bits are in common and you divide that by the number of bits that are set in either of the particular fingerprint bit strings.",
                    "label": 1
                },
                {
                    "sent": "So here's an example.",
                    "label": 0
                },
                {
                    "sent": "6 bits.",
                    "label": 0
                },
                {
                    "sent": "You have.",
                    "label": 0
                },
                {
                    "sent": "The 1st three are set, those ones are not.",
                    "label": 0
                },
                {
                    "sent": "Here it's a different pattern, and the first and third degree, so the similarities 2.",
                    "label": 0
                },
                {
                    "sent": "/ 5 So .4.",
                    "label": 0
                },
                {
                    "sent": "So this descriptor.",
                    "label": 0
                },
                {
                    "sent": "This similarity coefficient then calculates similarity between those two molecules and and that's important.",
                    "label": 0
                },
                {
                    "sent": "It considers both features in common and not uncommon, and that is that is.",
                    "label": 0
                }
            ]
        },
        "clip_40": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "Quite a different behavior from some other coefficients.",
                    "label": 0
                },
                {
                    "sent": "You can calculate an.",
                    "label": 0
                },
                {
                    "sent": "There's this illustration here, so table and an elephant are similar according to distance coefficient, because both cannot fly OK, because if you use the descriptors base of is that object able to fly, and that is not the case in both cases.",
                    "label": 1
                },
                {
                    "sent": "Then the distance is 0, so this particular representation assigns the distance to zero, which you might misinterpret as a similarity of 1 between two objects.",
                    "label": 0
                },
                {
                    "sent": "OK, so the point here is that similarity coefficients and distance coefficients as something completely different, and that's numerically illustrated here.",
                    "label": 0
                },
                {
                    "sent": "So if you have two bit strings of five bits each and in one case for bids are set here, 5 bits are set, your similarity would be .8 and your distance is 1.",
                    "label": 0
                },
                {
                    "sent": "So one bit is different and the same distance would be achieved in this particular case.",
                    "label": 0
                },
                {
                    "sent": "But so the distance is 1, one bit is different again, but that any model coefficients or the similarity would be hugely different OK, and so you have to be careful with those terms similarity and distance and dissimilarity as we see on the next slide.",
                    "label": 1
                },
                {
                    "sent": "They mean something quite different and often similarity coefficients behave more.",
                    "label": 0
                },
                {
                    "sent": "In line with what might be expected psychologically, they're actually interesting papers of Twersky in the 70s and 80s who looked into how humans perceive similarity, and this is actually where much of the similarity between molecules was based on almost whiskey.",
                    "label": 0
                }
            ]
        },
        "clip_41": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "And is this the similarity actually the opposite of similarity?",
                    "label": 1
                },
                {
                    "sent": "That's what you might assume, because formerly, you could say this similarity could be seen as one over similarity of 1 minus similarity, but in practice that's quite often not the case, because if you have a bit string and you have a number of features that agrees between particular objects, that is a much higher resolution in the near similarity range.",
                    "label": 0
                },
                {
                    "sent": "OK, if basically nothing agrees, you don't have a resolution anymore now, so similarity is formally.",
                    "label": 0
                },
                {
                    "sent": "If you wish is the opposite of dissimilarity, but because of the way how similarity is defined, you have a much better resolution in the similarity arrange so you cannot say much about objects that are very far away.",
                    "label": 0
                },
                {
                    "sent": "There is implications for diversity selection of compounds, so don't just use Tanimoto coefficient which is defined for similarity and expected to Topeka properly diverse set.",
                    "label": 0
                }
            ]
        },
        "clip_42": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "And yeah, its shape is important and similarity can be very misleading because sometimes very small changes and similarity kind of huge effect is for example here the molecule.",
                    "label": 1
                },
                {
                    "sent": "And if that our group is methyl or so.",
                    "label": 0
                },
                {
                    "sent": "In this case it would be a caffeine if there's a methyl group here, and if there's a hydrogen, it's a different molecule and you see a 10,000 fold difference in activity.",
                    "label": 0
                },
                {
                    "sent": "OK, so similarity is a global property, sometimes local small differences matter and that can be difficult to.",
                    "label": 0
                },
                {
                    "sent": "Pick up.",
                    "label": 0
                }
            ]
        },
        "clip_43": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "And so similarity is not an intrinsic property of objects, and so it depends on the context.",
                    "label": 1
                },
                {
                    "sent": "So in some sense, that's why the question how similar to molecules is quite meaningless, because it depends on the question with respect to which property and molecular weight or by activity were one particular feature might matter.",
                    "label": 0
                },
                {
                    "sent": "So it always depends on the context and it's difficult to define quite often need to define that empirically, and quite often what is useful instead of using the external reference frame if you simply say how similar to molecules.",
                    "label": 0
                },
                {
                    "sent": "In the absence of any information, if you want to do ever quick and dirty solution, you can use similarity of fingerprints of course, but it's better if you have some external reference frame that tells you which similarity matters.",
                    "label": 0
                }
            ]
        },
        "clip_44": {
            "is_summarization_sample": false,
            "summarization_data": [
                {
                    "sent": "More than others in a given context, and what recently came up because we have more and more data is for example, that you use HTS fingerprints or docking based fingerprints or predicted targets or gene expression data and so on in order to define bioactivity profiles of molecules, because that defines the output of the system.",
                    "label": 0
                },
                {
                    "sent": "So you put a molecule into your system system response.",
                    "label": 0
                },
                {
                    "sent": "The same, although we have different compound, then the similarity is high, although the chemistry is quite dissimilar OK, the model response in a similar way, on the other hand.",
                    "label": 0
                },
                {
                    "sent": "If you look into if you have very similar compounds, you still get a different readout because you hit a different target, so then that readout similarity might not be very high.",
                    "label": 0
                },
                {
                    "sent": "So basically it depends on the response of the system on the external context on what you care about, so you have those HTS fingerprints based on pub chem essays.",
                    "label": 0
                },
                {
                    "sent": "For example, people at Russian Novartis did that.",
                    "label": 0
                },
                {
                    "sent": "Other companies as well.",
                    "label": 0
                },
                {
                    "sent": "We did that on predicted target based affinity fingerprints, predicted bioactivity profiles, and that representation is probably if you have enough data.",
                    "label": 0
                },
                {
                    "sent": "And that's a very good representation to use in my opinion.",
                    "label": 0
                },
                {
                    "sent": "So is it possible and sensible to?",
                    "label": 0
                }
            ]
        },
        "clip_45": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "Define molecular similarity, yeah, but you need to be careful.",
                    "label": 1
                },
                {
                    "sent": "So it depends on the context.",
                    "label": 0
                },
                {
                    "sent": "So if you have a context and you can define that is good to use that context, do I care about up and down regulation of that pathway?",
                    "label": 0
                },
                {
                    "sent": "Then that's a much much better readout to use than simply using fingerprints as a distance or similarity measure.",
                    "label": 0
                },
                {
                    "sent": "So choose a meaningful representation of similarity measure depending on their purpose.",
                    "label": 1
                },
                {
                    "sent": "OK, so.",
                    "label": 0
                }
            ]
        },
        "clip_46": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "Finally, so how would we design A screening library?",
                    "label": 0
                },
                {
                    "sent": "For example, for high content screens?",
                    "label": 0
                },
                {
                    "sent": "So the question is to have a manageable selection of some molecules for testing.",
                    "label": 1
                },
                {
                    "sent": "Manageable can be reasonably small, can be 10,000 molecules or so, sometimes even smaller because they have more complex essays than high throughput screening where it has up to a million or so you want to have a reasonable starting point for drug discovery, so you want to have good hit rates, but good means not too high and not too low, so something should hit, but if everything hits is also not a good starting point.",
                    "label": 0
                },
                {
                    "sent": "Suitable chemistry.",
                    "label": 0
                },
                {
                    "sent": "So it should be chemistry that soluble suitable for skin properties and so on.",
                    "label": 1
                },
                {
                    "sent": "And there are two aspects.",
                    "label": 1
                },
                {
                    "sent": "One question is, what's the space to sample from and how to sample from that space?",
                    "label": 0
                }
            ]
        },
        "clip_47": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "And one point here is, chemical space is not equal, so we had the biases in the data we heard about in the first part of the talk.",
                    "label": 1
                },
                {
                    "sent": "So we have much more data on historical protein targets.",
                    "label": 0
                },
                {
                    "sent": "For example, more explored chemical space.",
                    "label": 0
                },
                {
                    "sent": "I mean, if people for example establish synthetic routes, then those get over and over exploited.",
                    "label": 0
                },
                {
                    "sent": "So you have much more compounds in.",
                    "label": 0
                },
                {
                    "sent": "Collections which you can purchase from you have more Campbell data, so all that leads to bias and but there's also possibly something intrinsic and chemical space.",
                    "label": 0
                },
                {
                    "sent": "There were certain parts of chemical space are more likely to hit than others.",
                    "label": 0
                },
                {
                    "sent": "There was this paper for example, also from group at Novartis that looked at dark chemical meta.",
                    "label": 0
                },
                {
                    "sent": "So that means you have a compound collection.",
                    "label": 0
                },
                {
                    "sent": "In this case, let's say a million compounds or so, and they are tested in essays and so you do that a few dozen times a year or so in a large company, and they looked into compounds that were inactive in more than 100 essays.",
                    "label": 0
                },
                {
                    "sent": "So usually compounds would be expected.",
                    "label": 0
                },
                {
                    "sent": "You can do some permutation tests to be active after a certain number of screens, so it's very unusual for compounds not to be active after 100 screens or so, and what you see is that actually properties are pretty similar between compounds that do hit and compounds that don't hit the question is, is there something intrinsic to the chemistry and that appears to be because they actually two ends of the spectrum?",
                    "label": 0
                },
                {
                    "sent": "One is very promiscuous, compounds compounds that bind to a large number of targets.",
                    "label": 1
                },
                {
                    "sent": "Many kinase inhibitors, TCR ligands and so on.",
                    "label": 0
                },
                {
                    "sent": "But you also have components that are hardly ever active and so the question is how to actually assemble the screening library in order to achieve a good balance between sampling chemical space and also achieving a suitable hit rates or not composite active to off.",
                    "label": 0
                }
            ]
        },
        "clip_48": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "And it's quite a number of different properties he would need to consider.",
                    "label": 1
                },
                {
                    "sent": "Some of them are probably more relevant in earlier stages than if you go into the clinic.",
                    "label": 0
                },
                {
                    "sent": "You don't really consider that early anyway, so you want to have components that are active but not too often that certainly a soluble enough that's effective.",
                    "label": 0
                },
                {
                    "sent": "That's often a confounding factor in experimental bioactivity data and compounds that are not obviously toxic because they would they would mess up your essay system as well.",
                    "label": 0
                },
                {
                    "sent": "And then of course you would you consider other practical factors at some stage is Tacoma synthesizer.",
                    "label": 0
                },
                {
                    "sent": "Lost and so on.",
                    "label": 0
                },
                {
                    "sent": "Can I patent it?",
                    "label": 0
                }
            ]
        },
        "clip_49": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "Representation matters, that's one part.",
                    "label": 1
                },
                {
                    "sent": "That's the part we partially covered before already, so we can use a chemical representation.",
                    "label": 0
                },
                {
                    "sent": "We can also go into shape.",
                    "label": 0
                },
                {
                    "sent": "So for example, there was a publication on the Pocket pocket home by rumor began 10 years ago or so.",
                    "label": 0
                },
                {
                    "sent": "So the question is, if you want to target all protein binding pockets.",
                    "label": 0
                },
                {
                    "sent": "So any kind of shape and direction properties you can enumerate the poker Dome and then you can use that for example to assemble a fragment based screening library or small molecule screening library in order to sample that diversity in order to theoretically target.",
                    "label": 0
                },
                {
                    "sent": "Every type of protein that is present in the poker tone.",
                    "label": 0
                },
                {
                    "sent": "You can also look into substructural diversity, so we have different ring systems.",
                    "label": 1
                },
                {
                    "sent": "Different schedules in there and or using functional diversity based on readouts.",
                    "label": 0
                },
                {
                    "sent": "But of course that is limited by the readouts you use, for example by the proteins you can currently target.",
                    "label": 0
                },
                {
                    "sent": "OK, so this is by us again that I.",
                    "label": 0
                }
            ]
        },
        "clip_50": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "Alluded to in the beginning.",
                    "label": 0
                },
                {
                    "sent": "So this representation aspect, probably functional readouts, is a good choice.",
                    "label": 0
                },
                {
                    "sent": "And then there's the question how to pick compounds and that can be very tricky because if you go for overall maximum diversity, if you visualize chemical space at the borders, you basically only find rubbish.",
                    "label": 0
                },
                {
                    "sent": "You find a very unusual compounds if you do that with pubchem, for example, and you're looking for compound paths with maximum distance, low similarity, and then you find chemistry you wouldn't like to screen for, so you probably would have some kind of maximum optimization, or your classifier compounds.",
                    "label": 0
                },
                {
                    "sent": "So you want to maximize the minimum distance between compounds.",
                    "label": 1
                }
            ]
        },
        "clip_51": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "But there's also conceptual problem actually.",
                    "label": 0
                },
                {
                    "sent": "With a diversity selection of compounds and the question is can we actually pick a representative subset.",
                    "label": 1
                },
                {
                    "sent": "And I would say, and there's some papers that argue that as well, that's actually conceptually not really possible.",
                    "label": 0
                },
                {
                    "sent": "Of course we can pick diverse compounds, but can we really handle that high dimensional space?",
                    "label": 0
                },
                {
                    "sent": "So we operate in a very high dimensional space, say it's 100 dimensional, few 100 dimensional.",
                    "label": 0
                },
                {
                    "sent": "No one can really say well there is.",
                    "label": 0
                },
                {
                    "sent": "This is chemical space.",
                    "label": 0
                },
                {
                    "sent": "Quite tricky is very high dimensional.",
                    "label": 1
                },
                {
                    "sent": "You cannot project it onto D and do proper selection and so if the bioactivity landscape is very smooth, we could probably pick.",
                    "label": 0
                },
                {
                    "sent": "Representative examples, but only if the dimensionality is not high.",
                    "label": 0
                },
                {
                    "sent": "But if we have if the impact of activity clips is profound, we can never expect to sample that space.",
                    "label": 1
                },
                {
                    "sent": "OK, and because if you have a 900 dimensional space in your, changing some part of your molecule, change by activity, that's a huge space.",
                    "label": 0
                },
                {
                    "sent": "You will not be able to and practice sample that space so you could for example, stay in quite a small area of chemical space and that would be as diverse as sampling from the much larger space.",
                    "label": 0
                },
                {
                    "sent": "OK, because you have changes in bioactivity evening, that's more.",
                    "label": 0
                },
                {
                    "sent": "Area of chemical space.",
                    "label": 0
                }
            ]
        },
        "clip_52": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "There also some practical aspects, though if you want to assemble your screening library once that screens are not perfect, of course they're noisy.",
                    "label": 1
                },
                {
                    "sent": "So if you want to learn about the activity of a compound quite often we would like to know about the confidence of that measurement.",
                    "label": 1
                },
                {
                    "sent": "So you want to have, let's say 5 similar compounds or so.",
                    "label": 0
                },
                {
                    "sent": "One scaffold near screening set, because then what you can do is you can see do actually get a similar response, not the same necessary, but a similar response, and you can also know bout the SARC around the molecule already, which gives you some starting points for optimization.",
                    "label": 0
                },
                {
                    "sent": "It's not just that we want to diverse molecules, the question is also what can you use that information for.",
                    "label": 0
                },
                {
                    "sent": "In practice, once you found some active molecules.",
                    "label": 0
                }
            ]
        },
        "clip_53": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "What do you do empirically?",
                    "label": 0
                },
                {
                    "sent": "And that's virtually all the big companies I think.",
                    "label": 0
                },
                {
                    "sent": "I do that to some extent.",
                    "label": 0
                },
                {
                    "sent": "Quite often have a small set of compounds that are more affection annotated.",
                    "label": 0
                },
                {
                    "sent": "So Novartis 20 years ago.",
                    "label": 0
                },
                {
                    "sent": "So it was called the climax box.",
                    "label": 0
                },
                {
                    "sent": "It's probably called differently than other companies, so we have a set of a few 1000 up to 10,000 or so usually compounds that are mode of action known and annotated.",
                    "label": 0
                },
                {
                    "sent": "So that's it.",
                    "label": 0
                },
                {
                    "sent": "Drugs on the market quite often, but it can also be probe compounds.",
                    "label": 0
                },
                {
                    "sent": "Because there's this drugs on the market don't need to be particularly selective.",
                    "label": 0
                },
                {
                    "sent": "Probs need to be because we want to probe a pathway.",
                    "label": 0
                },
                {
                    "sent": "Drug only needs to be safe in the clinic and that's a different question, so probably would rather put in more probes in this type of data set.",
                    "label": 0
                },
                {
                    "sent": "Quite usually you would like to have multiple representatives from out of action, trust with different schedules so you can see is the effect scaffold related, or does it actually translate to different scaffolds that target the same protein and then you can have a set of 1000 or 10,000 or so of compounds that target different biological pathways and this is probably a good way.",
                    "label": 1
                },
                {
                    "sent": "If you have a functional biological readout to assemble screening library, but this stays within well annotated chemical and bioactivity space again, so it goes back to the bias again, so we can only pick those compounds that are diverse in their bioactivity space.",
                    "label": 0
                },
                {
                    "sent": "We know already which might be limiting for the future.",
                    "label": 0
                }
            ]
        },
        "clip_54": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "So we need to so diversity library design.",
                    "label": 1
                },
                {
                    "sent": "So we need to define what's relevant.",
                    "label": 0
                },
                {
                    "sent": "Chemical space of interest, difficult to do.",
                    "label": 1
                },
                {
                    "sent": "Looking forward with new targets, new areas of chemistry, but we don't have much information right now.",
                    "label": 0
                },
                {
                    "sent": "We need to have some kind of descriptors and similarity measure can be based on chemistry or effects, ideally based on context.",
                    "label": 1
                },
                {
                    "sent": "As I said, diversity selection, high dimensional space is not trivial at all.",
                    "label": 0
                },
                {
                    "sent": "It's a it's huge dimensionality and still true dimensionality and the number of data points.",
                    "label": 1
                },
                {
                    "sent": "If you can buy.",
                    "label": 0
                },
                {
                    "sent": "Whatever 300 million compounds.",
                    "label": 0
                },
                {
                    "sent": "Also from an.",
                    "label": 0
                },
                {
                    "sent": "I mean we cannot just cluster that and pick cluster centers that can be difficult with that number of compounds.",
                    "label": 0
                },
                {
                    "sent": "And, for example, annotated libraries might be a good starting point.",
                    "label": 0
                }
            ]
        },
        "clip_55": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "Yeah, so to summarize.",
                    "label": 0
                },
                {
                    "sent": "So drug discovery biology as well as chemistry in that area that's hugely biased from what you know in the past in protein space, but also chemical space.",
                    "label": 0
                },
                {
                    "sent": "If a starting point is known, we can do virtual screening.",
                    "label": 1
                },
                {
                    "sent": "Always pick a good descriptor as well as distance, measure an if no starting point is known we can design libraries for prospective screening and probably they should be based on some type of functional or bioactivity annotation.",
                    "label": 0
                },
                {
                    "sent": "Now, thanks.",
                    "label": 0
                }
            ]
        }
    }
}